

## **Carolyn J. Henry, DVM, MS**

601 Arbor Drive  
Columbia, Missouri 65201  
(573) 823-9361

### **Education:**

- 1994** **ACVIM Diplomate**, Specialty of Oncology
- 1991-1993** **MS**, Small Animal Surgery and Medicine, Auburn University  
Master's thesis entitled, "Pharmacokinetics and tolerance of a perfluorochemical emulsion for radiosensitization in dogs"
- 1986-1990** **DVM**, Cum Laude, College of Veterinary Medicine, Auburn University.
- 1983-1986** **BS**, Magna Cum Laude (awarded June, 1987), Eastern Kentucky University, Dual majors of Animal Science and Biology with a minor in Chemistry

### **Professional Experience:**

- 2013 – present** **Associate Dean for Research and Graduate Studies**  
College of Veterinary Medicine, University of Missouri, Columbia, MO
- 2012- present** **Associate Director of Research**  
Ellis Fischel Cancer Center; University of Missouri, Columbia, MO
- 2010- present** **Faculty Facilitator**  
One Health/One Medicine: The Convergence of Human and Animal Health  
Office of the Provost; University of Missouri, Columbia, MO
- 2010-present** **Assoc Director, Tom and Betty Scott Endowed Program in Veterinary Oncology**  
University of Missouri-Columbia
- 2008 – present** **Professor of Oncology**  
College of Veterinary Medicine and School of Medicine (dual appt)  
University of Missouri-Columbia
- 2003-2008** **Associate Professor of Oncology**  
College of Veterinary Medicine and School of Medicine (dual appt)  
University of Missouri-Columbia
- 2002-2010** **Director, Tom and Betty Scott Endowed Program in Veterinary Oncology**  
University of Missouri-Columbia
- 2001-2003** **Assistant Professor of Oncology**  
Department of Medicine, Division of Hematology and Oncology; School of Medicine,  
University of Missouri (dual appt)
- 1997-2003** **Assistant Professor of Oncology**  
Department of Veterinary Medicine and Surgery  
College of Veterinary Medicine, University of Missouri
- 1993-1997** **Assistant Professor**  
Department of Veterinary Clinical Sciences  
College of Veterinary Medicine, Washington State University
- 1991-1993** **Oncology Resident**  
Department of Small Animal Surgery and Medicine  
College of Veterinary Medicine, Auburn University
- 1992-1993** **Emergency Care Veterinarian**  
Columbus Animal Emergency Center, Columbus, Georgia
- 1991-1993** **Emergency Care Veterinarian**  
Montgomery Animal Emergency Clinic, Montgomery, Alabama
- 1990-1991** **Associate Veterinarian**  
Animal Care Center, Prattville, Alabama

**Licenses to practice veterinary medicine:**

Alabama #4116 (inactive)  
Georgia #004716 (inactive)  
Missouri #006026

**Administrative and Service Positions:**

2017 Animal Health Research Symposium Planning Committee, Kansas City Area Life Sciences Institute  
One Health Commission Board of Directors, 2016 - present  
ACVIM Large Animal Internal Medicine Audit Committee, 2016 - present  
Canines-n-Kids Foundation Board of Directors, 2016 - present  
National Cancer Institute Site Visit Team; March/April 2016  
    HIV/AIDS Malignancy Branch  
    Molecular Imaging Program  
    Comparative Oncology Program  
Students for One Health Club, University of Missouri faculty advisor, 2016-present  
2016 Animal Health Research Symposium Planning Committee, Kansas City Area Life Sciences Institute  
Washington University, Auburn, Missouri Consortium for One Health co-founder, 2015  
Associate Dean for Research and Graduate Studies; College of Vet Med, Univ of MO, 2013-present  
Puppy Up Foundation Advisory Board; 2014 - present  
World Congress on Controversies in Veterinary Medicine, Prague, Czech Republic, Oct 23-26, 2014 Co-chair  
Associate Director of Research, Ellis Fischel Cancer Center, Columbia, MO, 2012 – present  
Western Veterinary Conference Program Topic Coordinator, Oncology, 2010 and 2011  
Scott Endowed Program in Veterinary Oncology, University of Missouri  
    Assoc Director 2010-present  
    Director, 2002-2010  
Veterinary Cancer Society     Executive Committee Member 2002 - 2012  
    **President 2004-2006**  
    President-Elect and Newsletter Editor 2002-2004  
    Annual Conference Co-chair 2004  
    Member-at-Large 1998-2000  
American College of Veterinary Internal Medicine  
    **Specialty of Oncology President 2007-2010**  
    Board of Regents, 2007 - 2010  
    ACVIM Forum Moderator 1999, 2000, 2002, 2005  
    Nominating Committee, 2003-2005; 2010 – 2013; Chairman  
    Residency Training Committee, 2001- 2004; Chairman 2002-2004  
    General Exam Committee, 1998-2001  
    Oncology Examination Committee, 1995-1998; Chairman, 1997-1998  
AVMA Program Coordinator, Companion Animal Medicine, 2002, 2003, 2006, and 2007 Conventions  
Faculty Advisor, Student Chapter of the American Veterinary Society of Animal Behavior  
Western States Veterinary Conference Program Coordinator, Oncology, 2003  
MU Comprehensive Cancer Center Key Group Leader (Comparative Oncology), 2000-2005  
Barkley House development leader, 1999-present  
University of Missouri-Columbia Raptor Club Faculty Advisor, 1997-1999  
American Animal Hospital Association WSU Student Chapter Advisor, 1994-1997  
Small Animal Referral Medicine Section Coordinator, WSU, 1995-1997

## **Departmental, College, and University Committees**

Mizzou Health Advisory Board; 2014 – present  
Regulatory Affairs Steering Committee; 2014- present  
Council of Research Administrators; University of Missouri; 2013-present  
School of Medicine Dean’s Search Committee; 2013 – 2014  
CVM Graduate/Resident Training Committee, ex officio, chair; 2013-present  
CVM Research Committee, ex officio chair; 2013 – present  
CVM Diversity Committee, 2013-present  
CVM Visiting Lecturer Committee, 2013 – 2015  
Ellis Fischel Cancer Center Advisory Board, ex officio member, 2012 - present  
Ellis Fischel Cancer Center Executive Committee; 2012 – present  
School of Medicine Scientific Peer Review Committee, 2008-present  
CVM Vision 2020 Strategic Planning Committee; appointed by Dean, 2011  
Ellis Fischel Self Study Committee; 2010 - 2012  
Status of Women Committee, University of Missouri; appointed by Chancellor 1/2010 – 8/2011  
Administrator’s Evaluation Committee (elected as Veterinary Med and Surgery representative) 2010  
Promotion and Tenure Committee, Dept of Veterinary Medicine and Surgery, 2008 – 2011, chair 2010  
MU Dept. of Veterinary Medicine and Surgery Oncology Search Committee, Chair 2007  
Ellis Fischel Cancer Center-Cancer Education Subcommittee, 1999-2012  
MU Dept. of Veterinary Medicine and Surgery Comparative Medicine Advisory Committee, 2007  
MU Dept. of Veterinary Medicine and Surgery Clinical Guest Lectures Committee, 2006-2013  
MU Dept of Path. & Anatomical Sci, School of Medicine, Pathology Search Committee 2005- 2007  
MU Dept. of Veterinary Medicine and Surgery Pharmacy Committee, 2006-present (co-chair)  
MU Dept. of Veterinary Medicine and Surgery Adjunct Appointments Committee, 2006- 2013  
MU CVM ad hoc Committee on Guidelines for Promotion of Non-Tenure Track Faculty, 2007  
MU College of Veterinary Medicine Admissions Committee Alternate, 2007  
MU College of Veterinary Medicine Committee on Research, 2004  
MU Dept. of Veterinary Medicine and Surgery Medical Records Committee, 2000-2003  
MU Dept of Pathobiology, Anatomic Pathology Search Committee, 2001- 2003 and 2006-2007  
MU Dept. of Veterinary Medicine and Surgery Referral Medicine Search Committee 2001-2003  
VM Zalk Endowed Chair in Angiogenesis Search Committee, 2000-2002  
College of Veterinary Medicine Mission Enhancement Infrastructure Needs Committee, 2000  
College of Veterinary Medicine Tumor Virology Search Committee, 2001  
MU Dept. of Veterinary Medicine and Surgery Oncology Search Committee, Chair 2001  
Tom and Betty Scott Endowed Professorship in Oncology Search Committee, 1998-2001  
MU Dept. of Veterinary Medicine and Surgery Neurology Search Committee, 1998-2002  
MU Dept. of Veterinary Medicine and Surgery Committee on Research 1997-2000  
MU Department of Veterinary Medicine and Surgery Pharmacy Committee 1997-2001  
Kraeuchi Endowed Professorship in Ophthalmology Search Committee, 1997-2000  
MU College of Veterinary Medicine Admissions and Scholarship Committee Alternate ‘97-98  
MU Dept. of Veterinary Medicine and Surgery Radiology Search Committee, 1997-2002  
MU College of Veterinary Medicine Tumor Biologist Search Committee, Chair, 1998-1999  
MU Dept. of Veterinary Medicine and Surgery ICU Search Committee, 1997-1998  
MU Diagnostic Laboratory Immunohistochemistry Search Committee, 1997-1998

### **Memberships:**

CTSA One Health Alliance, 2016 – present  
Auburn University CVM Centennial Club, 2016  
Institute for Clinical and Translational Science member, 2015-present  
Women in Cancer Research, 2014-present  
University of Missouri Columns Society, 2014-present  
American Association for Cancer Research, 2014-present  
Griffiths Leadership Society for Women, 2014-present  
National Academies of Practice, Fellow, 2014-present  
Auburn University Alumni Association Life Member  
One Health Commission; leader level member, 2013-present  
American Association of Veterinary Medical Colleges (One Health Committee) 2013-present  
Sigma Xi Scientific Research Society, 2002-present  
Phi Zeta Veterinary Honor Society, 1999-present  
Veterinary Cooperative Oncology Group, 1996-present  
American College of Veterinary Internal Medicine, Diplomate, Specialty of Oncology, 1994  
Veterinary Cancer Society, 1993-present  
Intl Soc for Artificial Cells, Blood Substitutes, & Immobilization Biotechnology 1992-present  
American Veterinary Medical Association, 1990-present  
American Animal Hospital Association, 1994-1997  
Missouri Veterinary Medical Association, 1998-present  
American Association for the Advancement of Science, 1993-1995  
Central Alabama Veterinary Medical Association, 1991-1993  
American Mensa Ltd., 1990-present

### **Honors and Awards:**

ACVIM Robert W. Kirk Award for Professional Excellence, 2017  
SAVMA Public Health and Community Outreach Teaching Excellence Award, 2017  
Griffiths Leadership Society, 2014  
National Academies of Practice Distinguished Fellow, 2014  
Veterinary Medicine Academy Distinguished Practitioner & Fellow, 2014  
Dean's Impact Award; College of Veterinary Medicine, 2012  
Commonwealth of Kentucky Honorable Order of Kentucky Colonels, commissioned 2011  
America's Top Veterinarians, Consumers' Research Council of America, 2006  
Assoc for Women Veterinarians Outstanding Woman Veterinarian of the Year Nominee, 2006, 2007  
Distinguished Alumna Award, Eastern Kentucky University, 2004  
Young Achievers Award, Auburn University College of Veterinary Medicine, 2000  
Jerry Newbrey Teaching Scholar, Washington State University, 1994, 1996, 1997  
Westcott Clinical Teaching Scholar, Washington State University, 1995 and 1996  
Third Year Teaching Award, Washington State University, 1995

### **Grant and Manuscript Review**

Associate Editor, *Frontiers in Veterinary Science*, 2014- present  
Reviewer, *The Veterinary Journal*, 2013 – present  
Reviewer, *Veterinary and Comparative Oncology*, 2005 - present  
Reviewer, *American Journal of Veterinary Research* 2004-present  
Reviewer, *Journal of Veterinary Internal Medicine*, 1997-present  
Reviewer, *PLOSone* - 2014  
Editorial Board, *International Journal of Veterinary Medicine*, 2009 – 2014  
Reviewer, *Journal of Small Animal Practice*, 2010  
Reviewer, *The Journal of Gene Medicine*, 2008  
Reviewer, *Lung Cancer*, 2006  
Editorial Board, *Journal of the American Animal Hospital Association*, 2005-2012  
Reviewer, *Cancer Immunity*, 2005  
Reviewer, *Veterinary Record*, 2007  
Grant Reviewer, American Kennel Club/ Canine Health Foundation, 2000, 2004  
Grant Reviewer, MU Research Board, 2005, 2006  
Reviewer, *Journal of the American Veterinary Medical Association*, 2001, 2002, 2005  
Reviewer, *Compendium on Continuing Education for the Practicing Veterinarian*, 2002, 2005  
Reviewer, *Veterinary Medicine*, 2001, 2004  
Reviewer, *Veterinary Therapeutics*, 2001

### **Graduate Student Committees**

Dr. Shirley Chu, PhD Candidate, University of Missouri 2014 – 2018  
Dr. Sarah Rippey, MS Candidate, University of Missouri 2014 - 2017  
Dr. Brooke Fowler, MS Candidate, University of Missouri, 2010-2013  
Dr. Kerry Risetto, MS Candidate, University of Missouri, 2008-2011  
Dr. David Bommarito, MS Candidate, University of Missouri, 2008 – 2011 (chair)  
Dr. Kimberly Ringen, MS Candidate, University of Missouri, 2007 - 2010  
Dr. Candace E. Carroll, PhD Candidate, University of Missouri, 2005-2009  
Dr. J. Armando Villamil, PhD Candidate, University of Missouri, 2005- 2009 (chair)  
Ethan Balkin, PhD Candidate, Pathobiology Area, University of Missouri, 2006 - 2010  
Dr. Jeffrey N. Bryan, PhD Candidate, University of Missouri, 2005- 2007  
Dr. Wendi V. Rankin, MS Candidate, University of Missouri, 2005-2008 (chair)  
Farahnaz Rahmatpanah, PhD Candidate, Dept Pathol & Anatomic Sci, UMC, 2003-2007  
Dr. David A. Kunz, MS Candidate, University of Missouri, 2002-2005  
Dr. Kim D. Johnson, PhD Candidate, University of Missouri, 2003-2010 (chair)  
Dr. Jeffrey N. Bryan, MS Candidate, University of Missouri, 2002-2004  
Dr. Laura Dvorak, MS Candidate, University of Missouri, 2000-2004  
Dr. Stephanie Essman, MS Candidate, University of Missouri, 2000-2003  
Dr. Mary Lynn Higginbotham, MS Candidate, University of Missouri, 1999-2003 (chair)  
Dr. Jeff Bay, MS Candidate, University of Missouri, 1998-2001  
Dr. M. S. Buss, MS Candidate, Washington State University, 1994-1997 (chair)  
Dr. Lisa G. Britt, MS Candidate, Washington State University, 1994-1997

### **House Officer Advising**

Dr. Katie Fitzpatrick, Oncology Resident, University of Missouri and Iowa State University, 2011-2015  
Dr. Chamisa Herrera, Small Animal Medicine and Surgery Intern, University of Missouri, 2010-11  
Dr. Astrid Bigio, Small Animal Medicine and Surgery Intern, University of Missouri, 2009-2010  
Dr. David Bommarito, Oncology Resident, University of Missouri, 2008 – 2011 (primary advisor)  
Dr. Kerry Risetto, Oncology Resident, University of Missouri, 2008 -2011 (Selting primary advisor)  
Dr. Kim Ringen, Oncology Resident, University of Missouri, 2007 – 2010 (Selting primary advisor)  
Dr. Jarrod Vancil, Oncology Intern, University of Missouri, 2006-2007  
Dr. J. Armando Villamil, Oncology Resident, University of Missouri, 2005-2009 (primary advisor)  
Dr. Wendi Rankin, Small Animal Medicine and Surgery Intern, University of Missouri, 2004-2005  
Oncology Resident, University of Missouri; 2005 – 2008; Board-certified, 2008  
Dr. Kim D. Johnson, Oncology Resident, University of Missouri, 2003-2007; Board-certified, 2007  
Dr. Jeffrey N. Bryan, Oncology Resident, University of Missouri, 2002-2005; Board-certified, 2005  
Dr. Mary Lynn Higginbotham, Oncology Resident, University of MO 1999-02; Board-certified, 2002  
Dr. Emily Southward, Small Animal Emergency/Critical Care Resident, Univ of MO, 2001 -2005  
Dr. Dudley McCaw, Oncology Resident, University of MO 1999-2002; Board-certified, 2005  
Dr. Elizabeth Dunphy, Small Animal Emergency/Critical Care Resident, Univ of MO, 1999-2003  
Dr. Christine Graham, Small Animal Medicine and Surgery Intern, University of MO 2000-2001  
Dr. Lisa Luna, Small Animal Medicine and Surgery Intern, University of Missouri, 1998-1999  
Dr. Melissa Stoll, Small Animal Surgery Resident, University of Missouri, 1998-2002  
Dr. Paula Johnson, Small Animal Emergency and Critical Care Resident, Univ of MO, 1998-2002  
Dr. Ann Callahan, Small Animal Medicine and Surgery Intern, University of Missouri, 1997-1998  
Dr. M. S. Buss, Oncology Resident, Washington State University, 1994-1997; Board-certified, 1998.

### **Student Advisor for Undergraduate and Visiting Students**

- Erin Moses-University of Missouri; MU Gateway Summer Program 2005 student  
“Cancer in Juvenile Dogs”-database study of neoplastic disease in juvenile dogs-abstract presented at the 2005 Veterinary Cancer Society meeting; completed DVM degree at MU CVM
- Alexandrea Scott-Prairie View A & M University, TX; MU Gateway Summer Program 2004 student  
“Veterinary pediatric oncology”- Retrospective review of neoplastic disease in dogs <1 year of age. Case accrual is continuing in preparation for manuscript development
- Ginko Hayashi-University of California, Irvine; MU Gateway Summer Program 2003 student  
“Foot pad tumors in dogs and cats: Biological behavior and case outcome”  
Case accrual continuing through multi-institutional cooperative oncology group; study completion and manuscript preparation in collaboration with Dr. Kim Johnson
- Taracca Jackson-Delaware State University; MU Gateway Summer Program 2002 student  
“Primary renal tumors in dogs: a retrospective review” Abstract presented at the 2002 Veterinary Cancer Society Meeting and manuscript published in *Journal of Veterinary Internal Medicine*, 2006;20:1155-1160.
- Candace Carroll-Tougaloo College, Tougaloo MS; MU Gateway Summer Program 2002 student  
“Effect of pH variance on the specificity of the V-BTA test”  
Completed a PhD program in Biomedical Sciences at MU; Dr. Henry served on her committee
- Jodi Koontz-University of Missouri, 2002  
“Primary skeletal hemangiosarcoma in dogs” –manuscript in preparation; research presented at the 2002 Veterinary Cancer Society meeting in New York City
- Martine Moore- Hampton University, MU Gateway Summer Program 2001 student  
“Comparison of hematological and biochemical values for blood samples obtained via jugular venipuncture to those obtained via vascular access ports in cats”; manuscript published in the Journal of the American Veterinary Medical Association; DVM program at Virginia-Maryland College of Veterinary Medicine.
- Zamantha Watson -Oklahoma State University MU Gateway Summer Program 2000 student  
“A retrospective study of canine aural mast cell tumors”; abstract presented at 2000 Veterinary Cancer Society Meeting; manuscript publication pending completion by Dr. Mary Lynn Higginbotham
- Karen Kendrick- Merck-Merial Career Assistance Program 2000 student  
“Feline vaccine-associated sarcoma”
- Tracye Davis-MU Gateway Summer Program 1999 student;  
“Chemosensitivity testing as a treatment planning tool for dogs with lymphoma.”  
Presented at the 1999 Veterinary Cancer Society Meeting; Manuscript published in JAAHA  
Went on to a graduate program in Health Administration at Washington University
- Craig Clifford-Mississippi State University Extern 1999  
“Primary renal tumors in cats”; Presented at the 1999 Veterinary Cancer Society Meeting  
Published in Journal of Feline Medicine and Surgery; Completed an oncology residency at the University of Pennsylvania; Board certified in Specialty of Oncology
- Stephanie Ladd-Mississippi State University Extern 1998  
“Ocular Squamous Cell Carcinoma in Cattle”  
Completed Ophthalmology residency training program-University of California-Davis

## **TEACHING RESPONSIBILITIES**

### **VM-1, VM-II & VM III Didactic Courses:**

#### **VMS6989 Advanced Oncology of Companion Animals**

1 credit hour; elective didactic offered in Instructional Period 11; 16 class meetings

#### **VMS6050 Small Animal Medicine**

2.5 credit hour course; team taught in Instructional Period 10 each year; 4 oncology lectures

#### **VBMS5507 Veterinary Pharmacology**

3 credit hours; required team-taught course in Instructional Period 7; 4 oncology-related lectures

### **VM-III, VM-IV, Ross & St. George-Clinical Rotations**

#### **VMS6490 Small Animal Specialty Medicine 1 (Oncology)**

2 credit hours; required elective rotation; approximately 520 contact hours per year

#### **VMS6850 Small Animal Specialty Medicine II**

3 credit hours; elective oncology clinical rotation; approximately 520 contact hours per year

### **Graduate Student Courses:**

#### **VMS8022 Internal Medicine CPC**

1 credit hour; team-taught case presentation seminar course; 38 contact hours/year

#### **VMS8417 Advanced Oncology (course coordinator)**

2 credit hours; team-taught graduate oncology course offered every other year; 20 contact hours

#### **VMS8023 Internal Medicine Journal Review (course coordinator)**

1 credit hour; team-taught journal review seminar; 38 contact hours/year

#### **VMS8419 Veterinary and Comparative Oncology (course leader)**

1 credit hour; team taught with faculty from the School of Medicine 45 contact hours/year

#### **VMS8024 Medicine-Surgery-Pathology Conference**

1 credit hour; weekly case presentation seminar course; 45 contact hours/year

### **Course development:**

#### **Life Sciences Innovation & Entrepreneurship Graduate Certificate (Parker, JC)**

member of advisory committee; offered as of 2014

#### **Modular coursework in regulatory affair (Parker, JC)**

advisory committee member; \$40,000 course development award, Mizzou Advantage

#### **MU One Health Global Innovator Program (Henry, CJ)**

lead developer; negotiating partnership with UMKC and KCUMB



### **Grants Submitted to Sponsor**

Flesner B (PI) **Henry CJ** (Co-I). A randomized, masked, placebo controlled field study to determine efficacy and safety of Paccal Vet<sup>®</sup> in dogs with non resectable mammary carcinoma of stage III / IV. Oasmia, Uppsala, Sweden. 9/1/2015-8/31/2016. **\$130,360; funding approved, but trial on hold**

### **Grants/Fellowships Funded:**

**Henry CJ.** (PI) Comparative and Translational Oncology at MU: A One Health Approach to Cancer Care; Clara L. D. Jeffery Charitable Trust; 1/01/17 -12/31/17; **\$7,000.**

**Henry CJ** (PI). Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of Surgery and CANINE-OST-1 as Treatments for Newly Diagnosed Osteosarcoma in Dogs. ELIAS Animal Health, LLC. 5/1/15-4/30/17. **\$208,357**

**Henry CJ.** (PI) Comparative and Translational Oncology at MU: A One Health Approach to Cancer Care; Clara L. D. Jeffery Charitable Trust; 1/01/16 -12/31/16; **\$15,000.**

**Henry CJ** (PI). Pfizer-CCOGC Biospecimen Repository. Canine Comparative Oncology and Genomics Consortium (CCOGC). 7/15/2015-6/15/2016. **\$3,125**

Lattimer JC (PI), **Henry CJ** (Co-I). Precision Radiotherapy System (PRTS) for Permanent Interstitial Brachytherapy. ISO Therapeutic Group, LLC. 10/1/2015-12/31/2017. **\$245,025**

Bechtel S (PI), **Henry CJ** (Co-I). Melanocortin ligands in disease cachexia. Tensive Controls Inc. 7/10/15-7/9/16. **\$73,463**

**Henry CJ.** (PI) Comparative and Translational Oncology at MU: A One Health Approach to Cancer Care; Clara L. D. Jeffery Charitable Trust; 1/01/15 -12/31/15; **\$13,000.**

**Henry CJ.** (PI) Comparative and Translational Oncology at MU: A One Health Approach to Cancer Care; Clara L. D. Jeffery Charitable Trust; 1/01/14 -12/31/14; **\$13,500.**

Bryan JN (PI), Lattimer JC, Knapp S, Selting KA, **Henry CJ**, Bechtel-Axiak S. Pilot evaluation of <sup>18</sup>F-FDG-PET imaging to stage dogs with lymphoma. CVM Clinician Scientist Award, 2/1/13-1/31/14, **\$8000.**

Lattimer J (PI), Selting K (Co-I), Ketring A (Co-I), Bryan JN (Co-I), **Henry CJ** (Co-I), Axiak S (Co-I). A new radiopharmaceutical for the treatment of metastatic bone cancer. NIH SBIR. 7/1/12-6/30/14. **\$303,000.**

**Henry CJ.** (PI) Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Clara L. D. Jeffery Charitable Trust; 1/01/13 -12/31/13; **\$5,000.**

Bryan, JN (PI), **Henry CJ** (Co-I), Axiak SM (Co-I), Selting KA (Co-I) Development of artemisinin compounds for treatment of cancer. University of Washington (subcontract); 12/29-2011 – 03/10/2012; **\$148,770** (129,365 direct, \$19,405 indirect).

Axiak SM, Selting KA, **Henry CJ**, Bryan JN, Tate DJ. Pulse toceranib plus lomustine for the treatment of unresectable canine mast cell tumors. Colorado State Univ; 07/12/2011 – 09/30/2012; **\$15,120** (direct)

**Henry CJ**, Selting KA, Axiak SM. Use of Tavocept to improve efficacy and mitigate nephrotoxicity associated with cisplatin and piroxicam treatment of canine bladder cancer. Morris Animal Foundation grant D10CA-044; 10/01/10-12/31/13; **\$121,972** direct.

### **Grants/Fellowships Funded (cont'd):**

**Henry CJ.** (PI) Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Clara L. D. Jeffery Charitable Trust; 1/01/12 -12/31/12; **\$20,000.**

Selting KA (PI), Axiak SM (Co-I), **Henry CJ (Co-I)** Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. Ohio State University (subcontract); 03/01/2010 – 02/29/2012; **\$15,624** (\$12,400 direct; \$3,224 indirect)

**Henry CJ** (PI) Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Clara L. D. Jeffery Charitable Trust; 1/01/11-12/31/11; **\$20,000.**

**Henry CJ,** Assessment of Osteosarcoma Localization of Intravenously Administered 153Sm-DOTMP; IsoTherapeutics Group, LLC. 11/17/2010 – 11/16/2011; **\$27,270** (\$18,000 direct, \$9,270 indirect)

**Henry CJ,** Bryan JN, Selting KS, Axiak SM, Lui H. CCB-002 - The University of Missouri Pfizer-CCOGC Biospecimen Repository; Canine Comparative Oncology and Genomics Consortium; Frederick, MD; 10/15/2010 – 10/14/2011; **\$37,462** (direct) 9,366 (indirect)

**Henry CJ,** Bryan JN, Selting KS, Axiak SM, Lui H. CCB-001 - The University of Missouri Pfizer-CCOGC Biospecimen Repository; Canine Comparative Oncology and Genomics Consortium; Frederick, MD; 10/15/2010 – 10/14/2011; **\$12,487** (direct)

Volkert W (PI), **Henry CJ** (Co-PI), Axiak SM (Co-I). In Vivo Compatible and Readily Injectable Gold Nanoconstructs for Tumor Therapy. NIH-NCI (SBIR phase II); 9/30/10 – 9/29/12; **\$2,882,252**(50% indirect)

Selting KA, Decedue CJ, **Henry CJ,** Axiak SM. Phase I/II clinical trial of Nanotax® in tumor-bearing dogs. Morris Animal Foundation grant D10CA-047. 09/01/10-08/31/12; **\$79,612** (\$73,714 direct, \$5898 indirect).

Axiak SA, Lattimer J, **Henry CJ** (Co-I), Selting K, DeMello-Souza C, Cutler C, Katti K, Perry M. Safety of radioactive gold nanoparticles in the treatment of canine prostatic carcinoma. MU Institute for Clinical and Translational Science Award; 7/1/10 – 6/30/11; **\$50,000**

Souza CH, **Henry CJ,** Selting KA, Stack S. Evaluation of the effects of the retinoid isotretinoin and feline recombinant interferon-omega on a feline squamous cell carcinoma cell line. Winn Feline Foundation; 3/01/2010 – 2/28/2011; **\$11,210** total (chosen from 50 submitted proposals)

**Henry CJ (PI)** Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Clara L. D. Jeffery Charitable Trust; 1/01/10-12/31/10; **\$10,000.**

**Henry CJ (PI),** Selting KA, Srivastava P, Johnson KD, Owen, NK, Cook JL, Lattimer JC, O'Brien DP, Berent LM, Mann FA: The University of Missouri Pfizer-Canine Comparative Oncology Genomics Consortium Biospecimen Procurement Program Repository Award, Pfizer – CCOGC Biospecimen Repository, Frederick, MD; 10/15/09 – 4/14/2010; **\$19,300;** 10% effort

Bigio A, **Henry CJ.** Urinary polyamines as a biomarker of canine cancer. Phi Zeta Research Grant, 10/20/09 – 9/30/2010; **\$750.**

Selting KA (PI), Decedue CJ (PI-subcontract), Axiak SM (Co-I), **Henry CJ** (Co-I). Dose escalation safety study of Nanotax® in dogs. Kansas City Area Life Sciences Institute Research Development grant; 9/01/09 – 8/31/10; \$50,000; direct **\$45,455.**

### **Grants/Fellowships Funded (cont'd):**

Selting KA (PI), Reiner CR (Co-I), **Henry CJ** (Co-I), Ringen KA (Co-I). Comparison of percentage of T regulatory cells in dogs with spontaneously-occurring lymphoma following oral versus intravenous cyclophosphamide. American Kennel Club ACORN grant. 6/1/09-5/31/10. \$11,900 direct, \$952 indirect = **\$12,852** total; 1% effort.

Selting KA (PI), **Henry CJ (Co-I)**: COTC010 Evaluation of NHS-IL12-IL2 and NHS-IL12 fusion proteins in tumor bearing dogs. EMD Serono Biotech (through the COTC); 12/01/08 – 01/10/2010; **\$104,594**; direct \$83,675; (25% F & A rate); 1% effort.

**Henry CJ (PI)** Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Clara L. D. Jeffery Charitable Trust; 1/01/09-12/31/09; **\$10,000**.

**Henry CJ (PI)**, Selting KA, Srivastava P, Johnson KD, Owen, NK, Cook JL, Lattimer JC, O'Brien DP, Berent LM, Mann FA: The University of Missouri Pfizer-Canine Comparative Oncology Genomics Consortium Biospecimen Procurement Program Repository Award, Pfizer – CCOGC Biospecimen Repository, Frederick, MD; April 15, 2009 – Oct 14, 2009; **\$31,300**, 10% effort

**Henry CJ (PI)**, Selting KA (Co-I): COTC008 Evaluation of the mTOR inhibitor Rapamycin in dogs with osteosarcoma. Morris Animal Foundation (through the National Cancer Institute Comparative Oncology Trials Consortium); 7/01/08 – 6/30/09; **\$38,367**; direct \$35,525 (F&A = \$2842); 1% effort

**Henry CJ** and Lattimer JC (**Co-PIs**): Canine Osteosarcoma Research Program. The Gabriel Institute; April 2008 – July 2009, **\$20,000**, no indirects.

**Henry CJ (PI)**, Selting KA, Srivastava P, Johnson KD, Owen, NK, Cook JL, Lattimer JC, O'Brien DP, Berent LM, Mann FA: The University of Missouri Pfizer-Canine Comparative Oncology Genomics Consortium Biospecimen Procurement Program Repository Award, Pfizer – CCOGC Biospecimen Repository, Frederick, MD; April 15, 2008 – April 15, 2009; **\$54,600**, renewable; 10% effort

**Henry CJ (PI)**, Selting KA (Co-I), Lattimer JC (Co-I): Proof of Concept Study to evaluate the efficacy and safety of PF-2362376 in client-owned dogs with metastatic pulmonary lesions due to osteosarcoma. Pfizer Animal Health, Kalamazoo, MI; 2/12/08 – 2/11/10; **\$120,211**; direct \$80,408; F&A = \$39,803; study closed prematurely August 2008 based on corporate R & D decision

Selting KA, **Henry CJ**, Owen N, Rosenberg M. An open-label, dose-escalating study of Elsamitrucin in tumor-bearing dogs. Spectrum pharmaceuticals, Inc. 01/01/2008-12/31/2009; \$63,697 direct plus \$31,530 indirect (Total \$95,227); 1% effort

**Henry CJ (PI)** Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Clara D. Jeffery Charitable Trust; 1/04/08-12/31/08; **\$15,000**.

**Henry CJ**. Application of the VMDB to veterinary clinical medicine. College of Veterinary Medicine Clinician Scientist Award. Dec 1, 2007, **\$8,000**, no indirects.

Selting KA, Cook C, **Henry CJ (Co-I)**, McCaw DL. Phase 1 study of SPI-1620, a novel endothelin B agonist, in dogs with spontaneous solid tumors. Spectrum pharmaceuticals Inc. April 2007-March 2008; \$35,887 direct plus \$17,764 indirect (49.5% F&A), **total \$53,651**.

Bryan JN (PI), **Henry CJ (Co-I)**, Cutler C (Co-I), Ketring A (Co-I), Lattimer JC (Co-I). Systemic toxicity of <sup>177</sup>Lu-DOTMP administered intravenously to normal dogs. MU Research Reactor Partnership Initiatives and Scott Endowed Program in Veterinary Oncology. 9/1/06-9/1/07. **\$23,887**.

### **Grants/Fellowships Funded (cont'd):**

**Henry CJ (PI)** Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Clara L. D. Jeffery Charitable Trust; 1/08/07-12/31/07; **\$20,000**.

Rankin WV (PI), Green J (Co-I), **Henry C (Co-I)**, Schultz L (Co-I). Evaluation of a novel urine test for survivin in canine urinary bladder cancer. Granted by University of Missouri Veterinary Medicine and Surgery Committee on Research. 5/2006-5/2007; \$2,929.

**Henry CJ (PI)**; Selting KA (Co-I), McCaw DL (Co-I), Bryan JN (Co-I), Pope ER (Co-I). Evaluation of RGD targeted delivery of phage expressing TNF-alpha to tumor bearing dogs: Study 2; National Institutes of Health- National Cancer Institute Comparative Oncology Trials Consortium, Bethesda, MD, 08/28/2006-07/01/2007, **\$28,151**. 30% shared credit, 1% effort.

**Henry CJ (PI)**; Selting KA (Co-I), McCaw (Co-I), Bryan JN (Co-I), Pope ER (Co-I) Evaluation of RGD targeted delivery of phage expressing TNF-alpha to tumor bearing dogs: Study 1; National Institutes of Health- National Cancer Institute Comparative Oncology Trials Consortium, Bethesda, MD, 03/01/2006-01/01/2007, **\$31,900**; 30% shared credit, 1% effort.

**Henry CJ (PI)**, McCaw DL (Co-I), Selting KA (Co-I), Bryan JN (Co-I), Johnson KD (Co-I), A study to assess the efficacy and safety of ML-1,785,713 oral chewable tablets alone and in combination with cisplatin in dogs for the treatment of transitional cell carcinoma of the urinary bladder. Merial Limited; 9/30/04-6/30/07; **\$120,268**; PI; 8% effort; 44% shared credit.

**Henry CJ (PI)** Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Clara L. D. Jeffery Charitable Trust; 12/05-12/06; **\$15,000**.

Rankin WV (PI), **Henry CJ (Co-I; faculty mentor)** Expression and Identification of Survivin Splice Variants in Canine Urinary Bladder transitional Carcinoma. Phi Zeta Grant, Columbia, MO, 10/10/05-10/10/06; **\$750**.

Dhand R (PI), Selting KA (Co-I), **Henry CJ (Co-I)**, Branson K (Co-I), Reinero C (Co-I), Waldrep C (Co-I), Owen NK. Targeted Inhalation Delivery of Chemotherapy via Aeroprobe Intratracheal Catheter in Dogs. Trudell Medical International 10/1/05-9/30/06; **\$45,000**; 1% effort; 10% shared credit.

Selting KA, Robertson JD, Wang X, **Henry CJ**, McCaw DL, Bryan JN, Johnson KD, Rankin WV, Villamil JA, Owen N, Steffy J. ICP-MS quantification of plasma platinum concentrations following administration of oral Satraplatin for pharmacokinetic analysis. NSEI Reactor Utilization Grant (MU Research Reactor). 9/30/2005-9/29/2006; **\$8,000** direct.

**Henry CJ (PI)** Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Clara D. Jeffery Charitable Trust; 12/04-12/05; **\$1,500**.

**Henry CJ (PI)**, Selting KA (Co-I), McCaw DL (Co-I), Johnson KD (Co-I), Turk JR (Co-I), Bryan JN (Co-I). Comparison of mitoxantrone to doxorubicin for adjuvant therapy of feline mammary carcinoma. Scott Endowed Program in Veterinary Oncology Research Grants, Department of Veterinary Medicine and Surgery, University of Missouri; 6/15/04-6/15/05; **\$4,500**.

Dhand R, Selting K, Waldrep JC, Branson K, Bryan J, **Henry C**, Grueber R. Targeted Inhalational Delivery of Chemotherapy via the AeroProbe® Intratracheal Catheter in Dogs. American Respiratory Care Foundation Grant. Awarded October 2004; **\$10,000**

Johnson KD (PI), Glinskii VV (Co-I), **Henry CJ (Co-I)**. Evaluation of the efficacy of two carbohydrate-based galectin-3 inhibitors (modified citrus pectin and lactulosyl-L-leucine) in combination with doxorubicin for the treatment of hemangiosarcoma. Scott Endowed Program in Veterinary Oncology Research Grants, Department of Veterinary Medicine and Surgery, University of Missouri; 6/15/04-6/15/05; **\$4,032**.

### **Grants/Fellowships Funded (cont'd):**

**Henry CJ.** Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Jeffery Oncology Benevolent Fund; 12/03-12/04; **\$2,500**; project director.

Wynn Volkert (PI); M Lewis (Co-PI), Mark Hannink (Co-I), **CJ Henry** (Co-I), JC Lattimer (Co-I), A Singh (Co-I), S Lever (Collaborator), F Jia (Investigator), JN Bryan (Investigator). Center for Single Photon-emitting Cancer Imaging Agents. Natl Cancer Institute, 07/01/03-06/30/08, **\$6,937,979** direct.

**Henry CJ (PI)**, McCaw DL, Selting KA. Multicenter, placebo-controlled, double-blind randomized study of oral PHA-291639E in the Treatment of Dogs with Recurrent Mast Cell Tumors. Pharmacia Animal Health, 3/1/03-12/31/05; **\$53,050**; \$36,586 direct and \$16,464 indirect; 3% effort.

**Henry, CJ (PI)**, Turnquist SE (Co-I), Beissenherz M (Co-I). Evaluation of survivin as a molecular marker of canine bladder cancer. Scott Endowed Program in Veterinary Oncology Research Grants, Department of Veterinary Medicine and Surgery, University of Missouri; 6/15/03-6/15/04; **\$2,400**.

Development of GRP receptor-avid radiopharmaceuticals. National Cancer Institute (DHHS-RO1); 7/01/03-6/30/07; \$175,000 annual direct costs; \$40,250 annual indirect costs; total award, **\$861,000**; Co-Investigator, 5% effort, 5% shared credit; PI, Timothy Hoffman.

DL McCaw PI (50%), S Alexander (30%), **CJ Henry (10%)**, S Turnquist (10%) Proteomic Analysis of Canine Lymphomas,. MU Research Board July 1 2003- June 30, 2004, **\$39,783**.

Dudley McCaw (40%), Stephen Alexander (20%), **Carolyn Henry (10%)**, Susan Turnquist (10%), Kim Selting (10%), Jeff Bryan (10%). Proteomic Analysis of Canine Lymphoma to Determine Targets of Drug Resistance. Scott Endowment Research Fund; August 1, 2003-July 31, 2004. **\$4450**.

Bryan, JN (PI), Lewis MR (Co-PI), **Henry CJ (Co-I)**, Miller WH (Co-I), Copper-64-labeled antibodies for radioimmunotherapy of cancer. University of Missouri College of Veterinary Medicine Committee on Research; 12/1/02-11/30/03; **\$6000**; 2% effort.

Interactive case simulations in small animal internal medicine, cardiology, and oncology. University of Missouri-Columbia CVM Teaching Enhancement Funds, May 15, 2002; **\$5,580**; **Co-I:** PI, Leah Cohn

**Henry CJ (PI)**. Mitoxantrone and piroxicam versus piroxicam therapy alone for the treatment of feline oral squamous cell carcinoma. American Association of Feline Practitioners and the Academy of Feline Medicine 2002 Research Award; 3/1/02-12/31/05; **\$10,000**; 1% effort, 11% shared credit, **PI**.

Johannes C (PI), **Henry CJ** (Co-I). Mitoxantrone and piroxicam versus piroxicam therapy alone for the treatment of feline oral squamous cell carcinoma. Winn Foundation; 4/01/02-12/31/05; **\$14,250**, **Co-I**, 1% effort; 14% shared credit.

**Henry CJ (PI)** Novel therapeutic strategies for oral melanoma in dogs. Harold F. Bean Melanoma Research Fund, Ellis Fischel Cancer Center, 02/02-01/03; **\$5,000** designated for VMTH trial

**Henry CJ (PI)**. Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Jeffery Oncology Benevolent Fund; 1/02-12/02; **\$20,000**; project director.

**Henry CJ (PI)** Canine interleukin-2 Staphylococcus aureus enterotoxin immunotherapy for oral malignant melanoma. Heska Corporation, Fort Collins, CO; 9/01/01-8/31/02; **\$14,340.50**; 25% shared credit, 4% effort.

### **Grants/Fellowships Funded (cont'd):**

**Henry CJ (PI)**, Higginbotham ML, Lattimer JC, Stoll MR, McCaw DL, Tyler JW. Carboplatin radiosensitization for <sup>153</sup>Sm-EDTMP limb-salvage therapy of canine osteosarcoma; Morris Animal Foundation, Englewood, CO; 8/1/01-7/31/05; **\$256,031**; \$237,085 direct, \$18,946 indirect; 20% percent effort; 49% shared credit.

Bryan JN (PI; 7%), Lewis MR (Co-I; 2%), **Henry CJ (Co-I; 2%)**, Miller WH (Co-I; 2%). Copper-64-labeled antibodies for radioimmunotherapy of cancer. CVM Committee on Research Grant; 12/02-12/03; **\$6,000**; no indirects.

**Henry CJ (PI)**, Katti K (Co-I), Higginbotham ML (Co-I). Toxicity and pharmacokinetic study of MU Gold. MU Research Board; 5/01-5/02; **\$31,625**; 30% effort, one-year no-cost extension approved May 2002.

**Henry CJ (PI)** The effects of altered time intervals between surgery and radiation treatment on wound healing. UMC College of Veterinary Medicine COR Funds, 7/01/01-6/30/02; **\$5,500**; 8% effort.

McCaw DL (PI). 2001 Teaching enhancement for exam rooms. University of Missouri CVM Teaching Enhancement Funds; May 15, 2001; **\$9,800**; **Co-I**.

Allen G. (PI). Internet2-based high-quality video conferencing for instruction” University of Missouri-CVM Teaching Enhancement Funds, May 15, 2001; **\$11,250**, **Co-I**.

**Henry CJ**. Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Jeffery Oncology Benevolent Fund; 1/01-12/01; **\$30,000**; project director.

Higginbotham ML, **Henry CJ**, Katti KV. In vitro evaluation of MU-Gold on canine lymphoma tumor cell growth. Dept of Veterinary Medicine and Surgery Committee on Research Funds, 10/1/00 to 10/1/01; **\$4,500**.

Clifford C (PI), **Henry CJ** (Co-I) Evaluation of plasma vascular endothelial growth factor (VEGF), angiogenin (Ang) and basic fibroblast growth factor (bFGF) levels in normal dogs and dogs with hemangiosarcoma, osteosarcoma, mast cell tumor, and lymphosarcoma. University of Pennsylvania Departmental Research Grant, 10/1/00 to 10/1/01; **\$1,500**.

**Henry CJ**. Investigation of the VBTA test for detection of bladder cancer in domestic animals. Bion Diagnostic Sciences, Inc, Redmond, WA. 8/1/00 to 8/1/01: **\$1,250**; 2% effort.

Lewis MR (PI), **Henry CJ** (Co-I). Radiolabeling of a carcinoma-targeting immunotoxin for diagnostic imaging and radioimmunotherapy. University of Missouri College of Veterinary Medicine COR Fund, 6/1/00-6/1/01: **\$5,978**.

**Henry CJ (PI)**. Safety and efficacy evaluation of LDI-100 vs. conventional therapy in canine patients with malignant mast cell tumors. Milkhaus Veterinary Products, Inc., Delanson, NY, 5/19/00 –5/01/01; **\$36,758**; 2 % effort; 75% shared credit.

**Henry CJ**. Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Jeffery Oncology Benevolent Fund; 1/00-12/00; **\$50,000**; project director.

**Henry CJ (PI)** Investigation of feline cancer treatments. Cat Welfare Society, 12/99-12/00; **\$7,500**.

**Grants/Fellowships Funded (cont'd):**

**Henry CJ (PI).** Novel therapeutic strategies for oral melanoma in dogs. Harold F. Bean Melanoma Research Fund, Ellis Fischel Cancer Center, 10/99-12/00; **\$7,500** designated for VMTH trial.

Mackin A, Clifford C. Characterization of von Willebrand factor in dogs with hemangiosarcoma. Morris Animal Foundation 99PT-22, 8/99-8/00; **\$4,200; Collaborator.**

**Henry CJ (PI).** Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Jeffery Oncology Benevolent Fund; 1/99-12/99; **\$50,000**; project director.

**Henry CJ (PI).** Effect of chemotherapy on viral antibody titers in dogs with lymphoma. College Committee on Research, College of Veterinary Medicine, University of Missouri-Columbia, Columbia, MO, January 1999-December 1999; **\$4,040.**

**Henry CJ (PI).** Comparative Oncology at MU: Treating cancer in pets with the care and methodology of human medicine; Scott Charitable Trust; September 1998-September 1999; **\$9,900**; project director.

**Henry CJ (PI).** Efficacy of adjuvant mitoxantrone chemotherapy for the treatment of canine hemangiopericytoma following surgery. Department of Veterinary Medicine and Surgery COR Funds, University of Missouri-Columbia, Columbia, Missouri, 5/98-5/99; **\$4,478; PI.**

Johnson G (PI), **Henry CJ (Co-I).** The genetic basis for melanoma in Sinclair swine. CVM Committee on Research, University of Missouri-Columbia, Columbia, Missouri, 5/30/97-4/30/98; **\$10,000.**

**Henry CJ (PI).** Correlation of *in vitro* chemosensitivity assay results to clinical outcome in dogs with refractory lymphoma, Department of Veterinary Medicine and Surgery COR Funds, University of Missouri-Columbia, Columbia, Missouri, 5/97-5/98; **\$3,888.**

**Henry CJ (PI).** Phase II evaluation of combined mitoxantrone and cyclophosphamide cancer chemotherapy in dogs and correlation to responses predicted by *in vitro* clonogenic assay, Adler Foundation, Pullman, Washington, 6/96-6/97; **\$13,820.**

**Henry CJ. (PI)** Evaluation of hematologic responses of normal cats to single-agent mitoxantrone chemotherapy and recombinant human granulocyte colony-stimulating factor rescue therapy. Autzen, Pelley, Hitchings, Brink, and Farrell Funds, Pullman, Washington, 6/96-6/97; **\$17,290.**

MacEwen EG (PI). Combined liposome MTP-PE and GM-CSF for the treatment of canine oral melanoma. Morris Animal Foundation # 94CA-07, 9/94-9/98, **\$79,483, Collaborator.**

**Henry CJ (PI)** BR96 immunotherapy for spontaneous canine carcinomas. Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington, 5/95-12/96; **\$63,499.**

Buss MS (PI), **Henry CJ (Co-I).** Pharmacokinetic evaluation of cisplatin-impregnated polymethylmethacrylate in serum and tissue chamber fluid from healthy dogs. WSU Resident Award, 7/95-5/96, **\$5,000.**

**Henry CJ (PI).** Pilot single dose pharmacokinetic study of BMS-185660 in tumor-bearing dogs following IV or oral administration. Bristol-Myers Squibb Pharmaceutical Research Inst, Princeton, NJ, 7/1/94-12/31/94; **\$4,000; PI.**

**Henry CJ (PI).** Phase II evaluation of combined mitoxantrone and cyclophosphamide administration for treatment of various canine neoplasms and correlation to clonogenic assay for susceptibility to chemotherapy. Autzen & Brink Funds, Pullman, WA, 7/94-6/95; **\$20,000.**

### **Grants/Fellowships Funded (cont'd):**

Evaluation of rhG-CSF as a rescue agent for chemotherapy-induced myelosuppression in dogs. AmGen, Inc., 6/96-6/97; **\$14,000** materials grant; PI.

Evaluation of CTLA4-Ig as an agent to block antibody formation to BR96sFv-PE40. Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington, 9/95-10/95, **\$4,500** materials and services funding; PI.

BR96 sFv-PE40 immunotoxin for therapy of carcinoma in 10 dogs. Bristol-Myers Squibb Pharm. Research Institute, Seattle, WA, 1/94-1/95; **\$10,000** materials and services funding; PI.

Toxicity trial for BR96 immunotherapy in dogs. Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington, 4/95-5/95; **\$2,000**, materials/services funding; PI.

Phase II evaluation of combined mitoxantrone and cyclophosphamide administration for treatment of various canine neoplasms and correlation to clonogenic assay for cancer susceptibility to chemotherapy. Immunex Corporation, Seattle, WA, 7/94-6/95; **\$9,000** materials grant; PI.

### **Materials Transfer Agreements/Contracted Services**

Flesner BK (PI), **Henry CJ** (Co-I) Autologous In-Situ Therapeutic Vaccination with Intratumoral Hiltonol(Poly-ICLC) in Dogs or Cats with Measureable Cancer. Oncovir, Inc. 1/23/17- 04/01/18; **\$26,027**.

In vitro effects of Tavocept alone or in combination with piroxicam and/or cisplatin on cell viability in osteosarcoma and bladder cancer cell culture. BioNumerik, Inc., San Antonio, TX

Dose escalation study of Gemcitabine HCl for treatment of spontaneously occurring canine cancer. Elanco Animal Health, ad Division of Eli Lilly. 4/01/02-3/31/03; materials valuing **\$45,720**; PI

Mitoxantrone for treatment of feline oral squamous cell carcinoma and feline mammary carcinoma. Immunex Corporation. Seattle, WA, 3/01/02-12/01/03; materials valuing **\$8,794**; PI.

Mitoxantrone for the treatment of various malignant tumors in companion animals. Immunex Corporation. Seattle, WA, 7/7/00-6/1/02; materials valuing **\$20,697**; PI.

Mitoxantrone for the treatment of various malignant tumors in companion animals. Immunex Corporation. Seattle, WA, 5/1/99-8/31/00; materials valuing **\$59,500**; PI.

Development of a novel radiopharmaceutical agent to target carcinoma cells in vitro. Seattle Genetics, Inc, October 1998-January 2001; Co-investigator with Dr. Mike Lewis; MTA.

Use of mitoxantrone and piroxicam for treatment of canine transitional cell carcinoma of the bladder. Immunex Corporation. Seattle, WA, 3/1/98-5/1/99; materials valuing **\$177,400**; PI.



### **Embank Entries**

Rissetto KC, Rindt H, Selting KA, Villamil AJ, **Henry CJ**, Reiner CR. Canine lupus familiaris interleukin 2 receptor alpha chain precursor (OL2RA) mRNA, complete cds. GenBank, accession GU207463.1, January 19, 2010

Bryan JN, Jabbes M, Berent LM, Arthur GL, Taylor KH, Rissetto KC, **Henry CJ**, Rahmatpanah F, Rankin WV, Villamil JA, Lewis MR, Caldwell, CW. Canis lupus familiaris deleted in liver cancer mRNA, complete cds. GenBank, accession FJ602870, November 23, 2009.

RankinWV, **Henry CJ**, Turnquist SE, Turk JR, Beissenherz ME, Tyler JW, Green JA. Canis lupus familiaris baculoviral IAP repeat-containing 5 (BIRC5), mRNA, NCBI Reference Sequence NM\_001003019.1, December 21, 2008.

### **Collaborative Studies:**

“Preclinical evaluation of oral sulforaphane for the treatment and prevention of bladder cancer” Collaborative study with Dr. Brian Cornblatt, Nutramax Laboratories, Edgewood, Maryland and Drs. Paul Talalay and Jed Fahey, Johns Hopkins Medicine, Baltimore Maryland. 2/15 – present; product and \$2500 unrestricted gift.

“Molecular genetics and chromosomal alterations in canine and human prostate cancer.” Collaborative study with Dr. G. Steven Bova, James Buchanan Brady Urological Institute Research Laboratories, The Johns Hopkins Hospital, Baltimore, MD, 12/95- 1/2010).

“Clinical assessment of the PetScreen test for monitoring remission in dogs with lymphoma.” Collaborative study with Dr. Kevin Slater, Chief Executive, PetScreen Ltd, Nottingham, UK. 5/07 to 01/12.

Zhao S (PI), Strausberg R (Co-PI). Linking evolutionary genome instability to colon tumors. National Institutes of Health R01, 08/01/2006-7/31/2010, \$3,179,484; collaborator.

“Development of IL-2 gene therapy in the canine model of malignant melanoma” Collaborative study with Dr. Jim Schwarz of the Ellis Fischel Cancer Center, Columbia, MO, now Roswell Park Cancer Institute, Buffalo, NY, 1998-2001.

“Development of a tumor marker for diagnosis of spontaneous neoplasia in dogs and cats.” Collaborative study with Dr. Ed Stephen of Developmental Technologies International, Frederick, MD, and Roger Lallone, Brookwood Medical Center, Birmingham, AL, 11/94 -12/96.

## **Refereed Publications**

1. **Henry, CJ.** Salivary mucocoele associated with dirofilariasis in a dog. *Journal of the American Veterinary Medical Association* 1992;200:1965-1966.
2. **Henry, CJ, JA Hudson.** What's your diagnosis? Traumatic hernia in a dog. *Journal of the American Veterinary Medical Association* 1992;201:1773-1774.
3. **Henry CJ, WG Brewer Jr, SA Stutler.** Early-onset leukopenia and thrombocytopenia following doxorubicin chemotherapy for tonsillar squamous cell carcinoma in a dog. *Cornell Veterinarian* 1993;83:163-168.
4. **Henry CJ, WG Brewer Jr, RD Montgomery, KS Griffin, A Groth.** Clinical vignette: Adrenal pheochromocytoma in a cat. *Journal of Veterinary Internal Medicine* 1993;7(3):199-201.
5. **Henry CJ, Brewer WG, Henderson RA, Brawner WR.** Pharmacokinetics and tolerance of weekly Oxygent™ CA infusions in the dog. *Art Cells, Blood Subs, and Immob Biotech* 1994;22(4)1155-1160.
6. **Henry CJ, Dillon AR.** Clinical Update: Canine heartworm disease. *Journal of the American Veterinary Medical Association* 1994;204:1148-1151.
7. **Henry CJ, Brewer WG, Royer NS.** Tolerance of combined mitoxantrone and cyclophosphamide chemotherapy in normal cats. *Canadian Veterinary Journal* 1994;35:706-708.
8. Evermann JF, **Henry CJ, Marks SL.** Clinical Update: Feline infectious peritonitis. *Journal of the American Veterinary Medical Association* 1995;206:1130-1134.
9. de Jaham C, **Henry CJ.** Treatment of sarcoptic mange using milbemycin oxime. *Canadian Veterinary Journal*, 1995;36:42-43.
10. Meglino AJ, **Henry CJ, Marks SL, Lanevshci A.** Primary pulmonary neoplasia with thalamic metastasis in a cat. *Feline Practice*,1995; 23(2):21-23.
11. Tyler JW, Hassel DM, Long MT, **Henry CJ, Parish S.** Testicular hamartoma in a calf. *Veterinary Record*,1995;136:420.
12. **Henry CJ, Lanevshci A, Marks SL, Beyer JC, Nitschelm S, Barnes S.** Acute lymphoblastic leukemia, hypercalcemia, and pseudohyperkalemia in a dog. *Journal of the American Veterinary Medical Association* 1996;208, 237-239.
13. Bergman P, MacEwen EG, Kurzman IL, **Henry CJ, et al.** Carboplatin and amputation for treatment of dogs with osteosarcoma: 48 cases (1991-1993) *J Vet Intern Med* 1996;10:76-81.
14. Southwood LL, Parish SM, Tyler JW, **Henry CJ.** Atypical lymphosarcoma in a cow. *Veterinary Record* 1996;138:260.
15. **Henry CJ, Clark TP, Young DW, Spano JS.** Urine cortisol:creatinine ratio in healthy and sick cats. *Journal of Veterinary Internal Medicine* 1996;10:123-126.
16. **Henry CJ, Marks SL, Tyler JW.** Comparison of chemotherapy safety procedures used in veterinary teaching hospitals and human oncology centers. *Journal of the American Veterinary Medical Association* 1996;206:974-976.

### **Refereed Publications (cont'd):**

17. Padgett SL, Tillson DM, **Henry CJ**, Buss MS. Gingival vascular hamartoma with associated paraneoplastic hyperglycemia in a kitten. *Journal of the American Veterinary Medical Association* 1997;210:914-915.
18. **Henry CJ**, Tyler JW, Fields T, Brewer WG, Royer N. Accuracy of fluorocrit in determination of blood perflubron concentration. *Art Cells, Blood Subs, and Immob Biotech*, 1998;26(3):285-292.
19. **Henry CJ**, Buss MS, Lothrop CD. Veterinary uses of recombinant human granulocyte colony-stimulating factor. Part I: Oncology. *Compendium*, 1998;20:728-735.
20. Molander H, **Henry CJ**, Potter K, Tyler JW, Buss MS. Cutaneous mast cell tumor in cats: 32 cases (1991-1994). *J Amer Anim Hosp Assoc*, July/August 1998;34:281-284.
21. Rewerts JM, **Henry CJ**. Veterinary uses of recombinant human granulocyte colony-stimulating factor. Part II: Infectious diseases. *Compendium* 1998;20:823-828.
22. **Henry CJ**, Brewer WG, Tyler JW, Brawner WR, Henderson RA, Hankes GH, Royer N. Survival in dogs with nasal adenocarcinoma: 64 cases (1981-1995). *Journal of Veterinary Internal Medicine*, November/December 1998;12:436-439.
23. Buss MS, **Henry CJ**, Tyler JW, Tobias KS, Daoud S, Hoopes J, Moore MP. Systemic and tissue chamber fluid platinum concentrations released from cis-diamminedichloroplatinum II-impregnated polymethylmethacrylate in healthy dogs. *American Journal of Veterinary Research* 1999;60(3):280-283.
24. **Henry CJ**, Buss MS, Potter KA, Wardrop KJ. Mitoxantrone and cyclophosphamide combination chemotherapy for the treatment of various canine malignancies. *Journal of the American Animal Hospital Association* 1999;35:236-239.
25. **Henry CJ**, Turnquist SE, Smith A, Graham JC, Thamm DH, O'Brien M, Clifford CA. Primary renal tumors in cats: 19 cases (1992-1998). *Journal of Feline Medicine and Surgery* 1999;1:165-170.
26. Southwood LL, Schott HC, **Henry CJ**, Kennedy FA, Hines MT, Goer RJ, Hassel D. Disseminated hemangiosarcoma in the horse: 35 cases. *Journal of Veterinary Internal Medicine*; 2000;14:105-109.
27. MacEwen EG, Kurzman ID, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO, Phillips B, Zwahlen C, Obradovich J, Rosenthal RC, Fox LE, Rosenberg M, **Henry C**, Fidel J. Adjuvant therapy for melanoma in dogs: Results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. *Clinical Cancer Research* 1999;5(12):4249-58.
28. Chun R, Kurzman ID, Couto CG, Klausner J, **Henry C**, MacEwen EG. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: A pilot study. *Journal of Veterinary Internal Medicine* 2000;14(5):495-498.
29. Clifford CA, Mackin AJ, **Henry CJ**. Treatment of canine hemangiosarcoma: 2000 and beyond. *Journal of Veterinary Internal Medicine* 2000;14(5):479-485.

### **Refereed Publications (cont'd):**

30. Luna LD, **Henry CJ**, Higginbotham ML, Turnquist SE, Moore AS, Graham JC, Smith AN. Feline nonocular melanoma: A retrospective study of 23 cases. *Journal of Feline Medicine and Surgery* 2000;1:173-181.
31. Clifford CA, Hughes D, Beal MW, Mackin AJ, **Henry CJ**, Shofer FS, Sorenmo KU. Plasma vascular endothelial growth factor (VEGF) levels in normal dogs and dogs with hemangiosarcoma. *Journal of Veterinary Internal Medicine*,2001;15(2):131-135.
32. **Henry CJ**, McCaw DL, Buss MS, Pope ER, Tyler JW, Tate D, Russell L. Clinical assessment of chemosensitivity testing for treatment planning for dogs with cancer. *Journal of the American Animal Hospital Association*,2001; 37:165-171.
33. Canapp SO, Mann FA, **Henry CJ**, Lattimer JC. The use of a latissimus dorsi muscle flap for scapular reconstruction in a cat following fibrosarcoma excision. *Journal of the American Animal Hospital Association*,2001;37:283-289.
34. **Henry CJ**, McCaw DL, Brock KV, Stoker AM, Tyler JW, Tate DJ, Higginbotham ML. Association between cancer chemotherapy and canine distemper virus, canine parvovirus, and rabies virus antibody titers in tumor-bearing dogs. *Journal of the American Veterinary Medical Association*; 2001;219(9):1238-1241.
35. Urdaz JH, Tyler JW, **Henry CJ**, Gautz P, Turk JR, Turnquist SE. Primary cutaneous hemangiosarcoma in a cow. *Veterinary Record* 2001;149:306-307.
36. **Henry CJ**, Russell LE, Tyler JW, Buss MS, Sequin B, Cambridge AJ, Moore ME. Comparison of hematological and biochemical values for blood samples obtained via jugular venipuncture to those obtained via vascular access ports in cats. *Journal of the American Veterinary Medical Association*, 2002;220(4): 482-485.
37. Clifford CA, Hughes D, Beal MW, **Henry CJ**, Drobatz KJ, Sorenmo KU. Vascular endothelial growth factor concentrations in body cavity effusions in dogs. *Journal of Veterinary Internal Medicine* 2002; 164-168.
38. Fox DB, Cook JL, Kreeger JM, Beissenherz M, **Henry CJ**. Canine synovial sarcoma: a retrospective assessment of described prognostic criteria in 16 cases (1994-1999); *Journal of the American Animal Hospital Association*,2002; 38:347-355.
39. Moore AS, Nelson RW, **Henry CJ**, Rassnick KM, Kristal O, Ogilvie GK, Kintzer P. A diuresis protocol for administration of streptozotocin to dogs with pancreatic islet cell tumors. *Journal of the American Veterinary Medical Association*, 2002;221(6):811-818.
40. **Henry CJ**, McCaw DL, Turnquist SE, Tyler JW, Bravo L, Sheafor S, Straw RC, Dernell WS, Madewell BR, Jorgensen L, Scott MA, Higginbotham ML, Chun R. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. *Clinical Cancer Research* 2003;9:906-911.
41. Higginbotham ML, **Henry CJ**, Katti KV, Casteel SW, Dowling PM, Pillarsetty N. Preclinical tolerance and pharmacokinetic assessment of MU-Gold, a novel chemotherapeutic agent, in laboratory dogs. *Vet Therapeutics* 2003;4:76-82.

### Refereed Publications (cont'd):

42. **Henry CJ.** Management of transitional cell carcinoma. *Vet Clinics of North America Small Anim Practice* 2003;33:597-613.
43. **Henry CJ,** Tyler JW, McEntee MC, Stokol T, Rogers KS, Chun R, Garrett LD, McCaw DL, Higginbotham ML, Flessland KA, Stokes PK. Evaluation of a bladder tumor antigen test as a screening test for transitional cell carcinoma of the lower urinary tract in dogs. *Am J Vet Research* 2003;64(8):1017-1020.
44. Dvorak LD, Beaver DP, Ellison GW, Bellah JR, Mann FA, **Henry CJ.** Major glossectomy in dogs: a case series and proposed classification system. *J Am Anim Hosp Assoc* 2004;40:331-337.
45. Cahalane AK, Payne S, Barber LG, Duda LE, **Henry CJ,** Mauldin GE, Frimberger AE, Cotter SM, Moore AS. Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002). *J Am Vet Med Assoc* 2004;225(3):401-408.
46. Bryan JN, Lewis MR, **Henry CJ,** Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru G, Anderson CJ. Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy. *J Vet and Comparative Oncology* 2004;2:82-90.
47. Milner R, Farese J, **Henry C,** Selting K, Fan T, de Lorimier LP. Review: Bisphosphonates in veterinary oncology. *J Vet Intern Med* 2004;18:597-604.
48. **Henry CJ,** Buss MS, Hellstrom I, Hellstrom KE, Brewer WG, Bryan JN, Siegall CB. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinomas. *Clinical Cancer Research* 2005;11:751-5.
49. Weisse C, Soares N, Beal M, Steffy M, Drobotz K, **Henry CJ.** Survival times for dogs with right atrial hemangiosarcoma following surgical resection with and without adjuvant chemotherapy. *J Am Vet Med Assoc,* 2005;226:575-579.
50. **Henry CJ,** Brewer WG, Whitley EM, et al. Canine digital tumors: A Veterinary Cooperative Oncology Group retrospective study of 64 cases. *J Vet Intern Med* 2005;19:720-724.
51. Bryan JN, Jia F, Mohsin, J, Sivaguru G, Miller WH, Anderson CJ, **Henry CJ,** Lewis MR. Comparative uptakes and biodistributions of internalizing versus non-internalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. *Nuclear Medicine and Biology* 2005; 32(8):851-858.
52. Chun R, Garrett LD, **Henry CJ,** Wall M, Smith A, Azene NM. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. *Journal of the American Animal Hospital Assoc* 2005;41:382-387.
53. Rankin WV, **Henry CJ,** Kunz DA, Williams F. What is your diagnosis? Multiple myeloma. *J Am Vet Med Assoc* 2006;229(6):929-30.
54. Bryan, JN, **Henry CJ,** Turnquist SE, Tyler JW, Liptak J, Rizzo S, Sfiligoi G, Steinberg HS, Smith AN, Jackson T. Primary renal neoplasia of dogs: a retrospective review of 82 cases. *Journal of Veterinary Internal Medicine,* 2006;20:1155-1160.

### **Refereed Publications (cont'd):**

55. Suedmeyer WK, McCaw DL, **Henry CJ**. Attempted photodynamic therapy against patagial squamous cell carcinoma in an African rose-ringed parakeet (*Psittacula krameri*), *Journal of Zoo and Wildlife Medicine* 2007;38:587.
56. Johnson KD, **Henry CJ**, McCaw DL, Turnquist SE, Stoll MR, Kiupel M. Primary hyperaldosteronism in a dog with concurrent lymphoma. *J Vet Med A*, 2006;53:467-470.
57. McCaw DL, Chan AS, Stegner AL, Mooney B, Bryan JN, Turnquist SE, **Henry CJ**, Alexander H, Alexander S. Proteomics of canine lymphoma identifies potential cancer specific protein markers. *Clinical Cancer Research*, 2007;13:2496-2503.
58. Bryan JN, Keeler MR, **Henry CJ**, Bryan ME, Hahn AW, Caldwell CW. A population study of neutering status as a risk factor for canine prostate cancer. *The Prostate*, 2007;67:1174-1181.
59. Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, **Henry CJ**, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelium. *Neoplasia* 2007; 9:662-670.
60. **Henry CJ**, Downing S, Rosenthal RC, Klein MK, Meleo K, Villamil JA, Fineman LS, McCaw DL, Higginbotham ML, McMichael, J. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. *American Journal of Veterinary Research*, 2007;68:1246-1251
61. Johannes CM, **Henry CJ**, Turnquist SE, Hamilton T, Smith AN, Chun R, Tyler JW. Feline hemangiosarcoma: A retrospective study of 53 cases. *Journal of the American Veterinary Medical Association*, 2007;231(12):1851-6.
62. Rankin WV, **Henry CJ**, Turnquist SE, Turk JR, Beissenherz ME, Tyler JW, Rucker EB, Knapp DW, Rodriguez CO, Green JA. Evaluation of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma. *J Vet and Comp Oncol*, 2008, in press.
63. Cutler CS, Bryan JN, Chandia M, Irwin DJ, Engelbrecht HP, Told T, Lattimer JC, Hoffman T, **Henry CJ**, Ketring AR. Evaluation of <sup>177</sup>Lu-Labeled DOTMP and EDTMP. *J Labelled Compd Radiopharm.* 2007; 50:s446
64. Rankin WV, **Henry CJ**, Turnquist SE, Turk JR, Beissenherz ME, Tyler JW, Green JA. Comparison of the distribution of survivin among tissues from urinary bladders of dogs with cystitis, transitional cell carcinoma, or histologically normal urinary bladders. *American Journal of Veterinary Research*, 2008; 69:1073-1078.
65. Bryan JN, Taylor KH, **Henry CJ**, Selting KA, Rahmatpanah F, Lewis MR, Caldwell CW. DNA Methylation in Cancer: techniques and preliminary evidence of hypermethylation in canine lymphoma. *Cancer Therapy* 2008;6:137-148.
66. Selting KA, Waldrep C, Reinero C, Gustafson D, Mercier E, Branson KR, Kim DY, **Henry CJ**, Owen N, Hoopes PJ, Madsen R, Dhand R. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe® intracorporeal nebulization catheter. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, 2008;21(3):255-268.

### **Refereed Publications (cont'd):**

67. Bryan JN, Bommarito D, Kim DY, Berent LM, Bryan ME, Lattimer JC, **Henry CJ**, Englebrecth; Ketring A, Cutler C. Comparison of systemic toxicities of Lu-177-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs. *Journal of Nuclear Medicine Technology* 2009;37:45.
68. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, LeBlanc A, Newman S, Vail D, **Henry C**, et al. Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNF $\alpha$  to Cancer Vasculature. *PLoS One*, 2009;4(3)1-11.
69. London CL, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, **Henry CJ**, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following excision. *Clin Cancer Res* 2009;15:3856-3865.
70. McCormack D, Al-Shaer M, Goldschmidt BS, Dale PS, **Henry C**, Papageorgio C, Bhattacharyya K, Viator JA. Photoacoustic detection of melanoma micrometastasis in sentinel lymph nodes. *J Biomechanical Engineering* 2009;131:074519-1-5.
71. Bryan JN, Jabbes M, Berent LM, Arthur GL, Taylor KH, Rissetto KC, **Henry CJ**, Rahmatpanah F, Rankin WV, Villamil JA, Lewis MR, Caldwell CW. Hypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphoma. *BMC Genetics*, 2009;10(1):73.
72. Rissetto KC, Selting KA, Villamil JA, **Henry CJ**, Reinero CR. Cloning and expression canine CD25 for validation of an anti-human CD25 antibody to compare T regulatory lymphocytes in healthy dogs and dogs with osteosarcoma. *Veterinary Immunology and Immunopathology*, 2010; 135-137.
73. Kannan R, Boote E, Khan P, Cutler S, Jurisson S, Katti K, Chanda N, Shukla R, Axiak S, Lattimer J, **Henry C**, Zambre A. SU-GG-J-122: Therapeutic efficacy of 198Au nanoparticles using a canine model of prostate cancer. *Medical Physics* 2010;37(6):3173.
74. **Henry CJ**. Biomarkers in veterinary cancer screening: Applications, limitations, and expectations. *Veterinary Journal*, 2010; 165:10
75. Kuroki K, Britt LG, Franklin SP, **Henry CJ**. Skeletal-extraskeletal angiomatosis in a dog. *Veterinary Pathology*, online 13 May 2010; DOI: 10.1177/0300985810369904
76. Villamil JA, **Henry CJ**, Tyler JW, et al: Hormonal and sex impact on the epidemiology of canine lymphoma, *Journal of Cancer Epidemiology*, 2010; 591753:1
77. Bommarito DA, Kent MS, Selting KA, Henry CJ, Lattimer JC. Reirradiation of recurrent canine nasal tumors. *Veterinary Radiology and Ultrasound* 2010;52(2):207.
78. Rissetto K, Villamil JA, Selting KA, Tyler JW, **Henry CJ**. Trends in Feline Intestinal Neoplasia: an Epidemiologic Study of 1,129 Cases in the Veterinary Medical Database from 1964 to 2004. *J Am Anim Hosp Assoc* 2011;47: 28-36.
79. Webster JD, Dennis MM, Dervisis N, Heller J, Bacon NJ, Bergman PJ, Bienzle D, Cassali G, Castagnaro M, Cullen J, Esplin DG, Peña L, Goldschmidt MH, Hahn KA, **Henry CJ**, et al. Recommended guidelines for the conduct and evaluation of prognostic studies in veterinary oncology. *Vet Pathol* 2011;48(1):7-18.

### Refereed Publications (cont'd):

80. Bryan JN, Jia F, Mohsin H, Anderson C, Miller W, **Henry CJ**, and Lewis MR. Monoclonal Antibodies for Copper-64 PET Dosimetry and Radioimmunotherapy. *Cancer Biology and Therapy*, 2011;11:1001-7.
81. Bommarito DA, Lattimer JC, Selting KA, **Henry CJ**, Cohen M, Johnson GC. Treatment of malignant pheochromocytoma in a dog using 131I metaiodobenzylguanidine. *J Am Anim Hosp Assoc* 2011; 47(6):e188-194.
82. Axiak SM, Selting KA, Decedue CJ, **Henry CJ**, Tate D, Howell J, Bilof KJ, Kim DY. Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs. *Int J Nanomedicine* 2011;6:2205-12.
83. Selting K, Essman S, Reiner C, Branson KR, **Henry CJ**, Owen N, Guntur VP, Waldrep JC, Kim DY, Dhand R Targeted combined aerosol chemotherapy in dogs with radiological toxicity and grading. *J Aerosol Med Pulm Drug Deliv* 2011;24(1):43-8.
84. Villamil JA, **Henry CJ**, Bryan JN, Ellersieck M, Schultz L, Tyler JW, Hahn AW. Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms. *J Am Vet Med Assoc* 2011; 239(7) 960-5.
85. Selting KA, Wang X, Gustafson DL, **Henry CJ**, Villamil JA, McCaw DL, Tate D, Beittenmiller M, Garnett C, Robertson JD. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors. *J Vet Intern Med* 2011;25(4):909-15.
86. Fiocchi SC, Selting KA, Rosenberg MP, Kolli P, Lenaz G, **Henry C**. An open-label, dose-escalating phase I study of elsamitucin (SPI 28090) in treatment of malignant solid tumors in dogs. *J Vet Intern Med* 2011;25(4):897-902.
87. Vancil JM, **Henry CJ**, Milner RJ, McCoig AM, Lattimer JC, Villamil JA, McCaw DL, Bryan JN. Use of samarium Sm 153 lexidronam for the treatment of dogs with primary tumors of the skull: 20 cases (1986-2006). *J Am Vet Med Assoc*. 2012 Jun 1;240(11):1310-5
88. Statham-Ringen KA, Selting KA, Lattimer JC, **Henry CJ**, Green JA, Bryan JN, Jia F, Lewis MR. Evaluation of a B-cell leukemia-lymphoma 2-specific radiolabeled peptide nucleic acid-peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma. *Am J Vet Res*. 2012 May;73(5):681-8. doi: 10.2460/ajvr.73.5.681.
89. London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B, Ettinger S, Vaughan A, Alverez F, Hillman L, Kiselow M, Thamm D, Higginbotham ML, Gauthier M, Krick E, Phillips B, LaDue T, Jones P, Bryan J, Gill V, Novasad A, Fulton L, Carreras J, McNeill C, **Henry C**. Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumors. *Vet and Comparative Oncol* 2012;10(3):194-205.
90. Knapp DW, **Henry CJ**, Widmer WR, Tan KM, Moore GE, Ramos-Vara JA, Lucroy MD, Greenberg CB, Greene SN, Abbo AH, Hanson PD, Alva R, Bonney PL. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. *J Vet Intern Med*. 2013 Jan-Feb;27(1):126-33



### **Refereed Publications (cont'd):**

91. Jackson DE, Selting KA, Spoor MS, **Henry CJ**, Wiedmeyer CE. Evaluation of fixation time using Diff-Quik for staining of canine mast cell tumor aspirates. *Veterinary Clinical Pathology* 2013;42(1):99-102.
92. **Henry CJ**, Herrera C. Mast Cell Tumors in Cats: Clinical update and possible new treatment avenues. *Journal of Feline Medicine and Surgery* 01/2013;15(1):41-7.
93. **Henry CJ**, Bryan JN. Not lost in translation: how study of diseases in our pets can benefit them and us. *Missouri Medicine* 2013 May-Jun;110(3):216-9
94. Ray BK, Dahr S, **Henry C**, Rich A, Ray A. Epigenetic Regulation by Z-DNA Silencer Function Controls Cancer-Associated ADAM-12 Expression in Breast Cancer: Cross-talk between MeCP2 and NF1 Transcription Factor Family. *Cancer Research* 2013;73(2):736-44.
95. Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, Bryan JN, **Henry CJ**, Boote E, Tate DJ, Bryan ME, Katti KV, Kannan R. Gum Arabic Coated Radioactive Gold Nanoparticles Cause no Local or Systemic Toxicity in the Clinically Relevant Canine Model of Prostate Cancer. *Int J Nanomedicine* 2014;9:5001-11.
96. London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, **Henry CJ**, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study *PLoS One*. 2015 Apr 29;10(4):e0124889. doi: 10.1371/journal.pone.0124889. eCollection 2015.
97. **Henry CJ**. Unleashing the power of comparative oncology models in nanomedicine research. *European Journal of Nanomedicine* 2015;7:129-133.
98. Saba C, Paoloni M, Mazcko C, Kisseberth W, Burton JH, Smith A, Wilson-Robles H, Allstadt S, Vail D, **Henry C**, Lana S, Ehrhart EJ, Charles B, Kent M, Lawrence J, Burgess K, Borgatti A, Suter S, Woods P, Gordon I, Vrignaud P, Khanna C, LeBlanc AK. A comparative oncology study of iniparib defines its pharmacokinetic profile and biological activity in a naturally-occurring canine cancer model. *PLoS One* 2016 Feb 11(2):e0149194
99. Cai S, Zhang T, Forrest WC, Yang Q, Groer C, Mohr E, Aires DJ, Axiak-Bechtel SM, Flesner BK, **Henry CJ**, Selting KA, Tate D, Swarz JA, Bryan JN, Forrest ML. Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors. *Am J Vet Res*. 2016 Sep;77(9):1005-16. doi: 10.2460/ajvr.77.9.1005.
100. Stroud C, Dmitriev I, Kashentseva E, Bryan JN, Curiel DT, Rindt H, Reinero C, **Henry CJ**, et al. A One Health overview, facilitating advances in comparative medicine and translational research. *Clin Transl Med*. 2016 Aug;5(Suppl 1):26.
101. Qi X, Lam SS, Liu D, Kim DY, Ma L, Alleruzzo L, Chen W, Hode T, **Henry CJ**, Kaifi J, Kimchi ET, Li G, Staveley-O'Carroll KF. Development of inCVAX, *In situ* Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. *J Clin Cell Immunol* 2016 Aug;7(4).

### Refereed Publications (cont'd):

102. Kumar SR, Kim DY, **Henry CJ**, Bryan JN, Robinson KL, Eaton AM. Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors. *Vet & Comparative Onc* 2017 Jan 22. doi: 10.1111/vco.12297.

### Submitted Publications

103. Jamal SA, Parsel S, Friedlander E, Gustafson S, Shnyra A, Adegbulu A, Liu Y, Parrish N, **Henry C**, McArthur, C. QBC FAST Stain/LED microscopy is superior to Giemsa in specificity and accuracy as validated by the polymerase chain reaction. *Malaria Journal*: submitted
104. Sean M Parsel, Steven A Gustafson, Alexander A Shnyra, Edward Friedlander, Aderosoye J Adegbulu, Ying Liu, Nicole M Parrish, Syed A Jamal, Eve Lofthus, Leo Ayuk, Charles Awasom, **Henry C**, Carole P McArthur, Corresponding author: Mr. Sean Michael Parsel. Malaria overdiagnosis in Cameroon: diagnostic accuracy of QBC FAST Malaria Stain and LED microscopy versus Giemsa and bright field microscopy validated by polymerase chain reaction. *Parasites & Vectors* 2017: submitted.
105. **Henry CJ**, Flesner BK, Bechtel SA, Bryan JN, Tate DJ, Selting KA, Lattimer JC, Bryan ME, Grubb L, Hausheer F. Clinical evaluation of Tavocept to reduce diuresis time and volume in dogs with bladder cancer receiving cisplatin. *J Vet Intern Med* 2017, submitted.

### Non-refereed Publications:

1. Brewer WG Jr, **Henry CJ**. Immunotherapy of tumors with anti-idiotypic antibodies. *Veterinary Cancer Society Newsletter* 1992;16(4):9-10.
2. **Henry CJ**. Radioenhancement using perflurochemical emulsions. *Veterinary Cancer Society Newsletter* 1992;16(4):1-5.
3. **Henry CJ**. Safe handling of antineoplastic agents: a survey of protocols from 24 veterinary referral institutions. *Veterinary Cancer Society Newsletter* 1993;17(4):1-6.
4. **Henry CJ**. Diagnosis and treatment of canine transitional cell carcinoma of the urinary bladder. *Advances in Small Animal Medicine and Surgery* 1997;10(11):1-3.
5. **Henry CJ**. Toxicity and efficacy of mitoxantrone for treatment of various malignant tumors in companion animals. *Canine Practice* 1999;21:14-15.
6. **Henry CJ**. Oral neoplasia in dogs and cats. *Waltham Focus*; 2001; 11(4):4-11.
7. **Henry CJ**. How I treat halitosis in dogs. *Waltham Focus* 2003;13:3.
8. **Henry CJ**. Oncology Outlook: Osteosarcoma Part 1. *Veterinary Practice News* 2005;17(10):22.
9. **Henry CJ**. Oncology Outlook: Osteosarcoma Part II. *Veterinary Practice News* 2005; 17(11)
10. **Henry CJ**. The Bond and Beyond-A home away from home. *Vet Practice News* 2005;17(12):17.
11. **Henry CJ**. Reading Room -Review of Managing the Canine Cancer Patient by GK Ogilvie and AS Moore. *Compendium* 2007;29(1):50-51.
12. **Henry CJ**. Practice tips for onco-logical veterinary cancer care. *British Small Animal Veterinary Association Congress Times* 2007

### Books:

## **Cancer Management in Small Animal Practice**

**Henry CJ (chief editor)** and Higginbotham ML (assistant editor).

St. Louis: Elsevier Science, 2009

~400-page oncology textbook with a target audience of practicing veterinarians

### **Book Chapters:**

1. Henderson RA, Brewer WG, Brawner WR, **Henry CJ**. Clinical staging. In: Hahn KA and Richardson RC (eds). Veterinary Cancer Chemotherapy Philadelphia: Williams & Wilkins, 1994:23-45.
2. **Henry CJ**, Brewer WG. Drug interactions with antineoplastic agents. In: Kirk RW and Bonagura JD (eds). Current Veterinary Therapy XII Small Animal Practice Philadelphia: WB Saunders Co., 1995: 482-487.
3. **Henry CJ**. Safe handling of chemotherapy drugs. In: August JR (ed) Consultations in Feline Internal Medicine, vol 3. Orlando: WB Saunders Co. 1996:534-540.
4. Marks SL, **Henry CJ**. CVT Update: Diagnosis and treatment of systemic lupus erythematosus. In: Kirk RW and Bonagura JD (eds). Current Veterinary Therapy XIII Small Animal Practice Philadelphia: WB Saunders Co., 2000:514-516
5. **Henry CJ**. Chemotherapeutic Agents. In: Rosenthal RC (ed) Veterinary Oncology Secrets. Philadelphia: Hanley & Belfus, Inc. 2000:71-74.
6. **Henry CJ**. Update on vaccine-associated sarcomas. In: August JR (ed) Consultations in Feline Internal Medicine, vol 4. Orlando: WB Saunders Co. 2001:541-7.
7. **Henry CJ**. Chapter 5.3.10 Neoplastic Diseases of Small Intestines. In: Steiner, J (ed) Small Animal Gastroenterology. Hannover, Germany: Schlutersche GmbH & Co. 2008:211-215.
8. **Henry CJ**. Chapter 6.4.4 Neoplastic Diseases of Large Intestines. In: Steiner, J (ed) Small Animal Gastroenterology. Hannover, Germany: Schlutersche GmbH & Co. 2008:236-240.
9. **Henry CJ**. Mammary Cancer. In: Bonagura, J (ed) Kirk's Current Veterinary Therapy XIV. St. Louis: Elsevier Science, 2008:363-368
10. **Henry CJ**. Renal Neoplasia. In: Joe Bartges & David Polzin (eds) Nephrology and Urology of Small Animals. Ames: Wiley-Blackwell, 2009.
11. **Henry CJ**. Chapter 333: Paraneoplastic syndromes. In: Ettinger S, and Feldman E (eds) Textbook of Veterinary Internal Medicine, 7<sup>th</sup> ed; St. Louis: Elsevier, 2010
12. **Henry CJ**. Chapter 1 Section B: The Etiology of Cancer: Chemical, Physical and Hormonal Factors. In: Withrow SJ, Vail DM and Page RL (eds) Small Animal Clinical Oncology, 5<sup>th</sup> ed. St. Louis: Elsevier 2013: 15-20.
13. Macy DW and **Henry CJ**. Chapter 1 Section C: The Etiology of Cancer: Cancer-causing Viruses. In: Withrow SJ, Vail DM and Page RL (eds) Small Animal Clinical Oncology, 5<sup>th</sup> ed. St. Louis: Elsevier 2013: 20-29.
14. **Henry CJ**. Chapter 84: Mammary Cancer. In: Bonagura, J and Twedt DC (eds) Kirk's Current Veterinary Therapy XV. St. Louis: Elsevier Science, 2014, 375-380

### **Scientific Abstracts/ Proceedings:**

1. Bergman PJ, McEwen EG, Kurzman IL, **Henry CJ**, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 34 cases (1991-1992). *Proceedings of the 11th Annual Veterinary Cancer Society meeting*, Pacific Grove, California, October 1992.
2. **Henry CJ**. Salivary mucocele associated with dirofilariasis in a dog. *Animal Drug Therapy* 1992;2(11):1030.
3. **Henry CJ**, Brewer WG, Henderson RA, Brawner WR. Pharmacokinetics and tolerance of weekly Oxygent™ CA infusions in the dog. *Proceedings of the 5th International Symposium on Blood Substitutes*, San Diego, California, March 17-20, 1993;F23.
4. **Henry CJ**, Brewer WG, Henderson RA, Brawner WR. Tolerance and pharmacokinetics of Oxygent™ CA in dogs. *Proceedings: 11th Annual Forum of the ACVIM*, Washington, DC, May 20 -24, 1993;953.
5. **Henry CJ**, WR Brawner Jr, RA Henderson Jr, G Hankes, WG Brewer Jr, JW Tyler. Survival in dogs with nasal adenocarcinoma: a retrospective study of 42 cases. *Proceedings of the 13th Annual Veterinary Cancer Society meeting*, Columbus, Ohio, October 4-6, 1993.
6. **Henry CJ**, Brewer WG, Stutler SA. Early-onset leukopenia and severe thrombocytopenia following doxorubicin chemotherapy for tonsillar squamous cell carcinoma in a dog. *Veterinary Digest* 1994;3.
7. Marks SL, Rishniw SL, **Henry CJ**. Blind percutaneous gastrostomy: a new technique. *Proceedings: 12th Annual Forum of the ACVIM*, San Diego, CA, June 2-6, 1994;981.
8. **Henry CJ**, Brewer WG, Royer NS. Mitoxantrone/Cyclophosphamide chemotherapy in cats. *Proceedings: 14th Annual Veterinary Cancer Society Meeting*, Townsend, TN, October 23-25, 1994;55-56.
9. **Henry CJ**, Lothrop CD, Goodman S. Dogs receiving mitoxantrone and cyclophosphamide combination therapy do not produce clinically significant antibody titers to rhG-CSF. *Proceedings: 13th Annual Forum of the ACVIM*, Lake Buena Vista, Florida, May 18-21, 1995:1020.
10. **Henry CJ**, Buss MS, KJ Wardrop. Hematologic and clinical response to mitoxantrone and cyclophosphamide with rhG-CSF rescue in dogs. *Proceedings: 13th Annual Forum of the ACVIM*, Lake Buena Vista, Florida, May 18-21, 1995:1020.
11. Goodman SA, Brewer WG, **Henry CJ**, McPhearson CJ, Murray S, Abraha T, Lothrop CD. Antibody formation to rhG-CSF is delayed in dogs treated with chemotherapeutic drugs. *Proceedings: 13th Annual Forum of the ACVIM*, Lake Buena Vista, Florida, May 18-21, 1995:1004.
12. Marks SL, **Henry CJ**, Sweet D. Blind percutaneous gastrostomy in the dog. *Proceedings: 14th Annual Forum of the ACVIM*, San Antonio, Texas, May 23 -26, 1996.
13. **Henry CJ**, Buss MS, Garrigues U, Hellstrom I, Brewer WG, Hellstrom KE, Seigall CB. Presence of BR96 antigen on canine carcinoma cells. *Proceedings: 16th Veterinary Cancer Society Annual Conference*, Pacific Grove, CA, October 20-23, 1996:134.

**Scientific Abstracts/ Proceedings (cont'd):**

14. Buss MS, Molander H, Potter K, **Henry CJ**, et al. Predicting survival and prognosis in cats with cutaneous mastocytomas of varying histologic grade. *Proceedings: 16th Vet Cancer Society Annual Conference*, Pacific Grove, CA, October 20-23, 1996:56.
15. **Henry CJ**, Buss MS, Brewer WG, Garrigues U, Hellstrom I, Hellstrom KE, Siegall CB. Immunotherapy of canine carcinomas using the single-chain fusion protein, BR96 sFv-PE40. *Proceedings: 16th Veterinary Cancer Society Annual Conference*, Pacific Grove, CA, October 20-23, 1996:85.
16. **Henry CJ**. Clinical Use of rhCSF. *Proceedings: 15th Annual Forum of the ACVIM*, Lake Buena Vista, Florida, May 22-25, 1997:565-566.
17. Chun R, Kurzman ID, Couto G, Klausner J, **Henry C**, MacEwen EG. A preliminary evaluation of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. *17<sup>th</sup> Veterinary Cancer Society Annual Conference*, Chicago, IL, December 3-6, 1997.
18. **Henry CJ**, Turnquist S, Smith S, Graham J, Clifford CA. Primary renal tumors in cats: 17 cases (1992-1998). *18<sup>th</sup> Veterinary Cancer Society Annual Conference*, Estes Park, CO, October 2-6, 1998:54.
19. Russell LE, **Henry CJ**, Buss MS, Tyler JW, Seguin B, Cambridge AJ. A comparison of hematologic and biochemical values on samples obtained via jugular venipuncture to those obtained via venous access ports. *18<sup>th</sup> Veterinary Cancer Society Annual Conference*, Estes Park, CO, October 2-6, 1998:11.
20. **Henry CJ**. Oncologic Emergencies. *Proceedings of the North American Veterinary Conference*, Orlando, Florida, January 9-13, 1999.
21. **Henry CJ**. Managing Mast Cell Tumors: Chemotherapy and Photodynamic Therapy. *Proceedings of the North American Veterinary Conference*, Orlando, Florida, January 9-13, 1999.
22. **Henry CJ**. Surgery and adjuvant therapy of sarcomas: Vaccine-associated feline sarcoma. *Proceedings of the North American Veterinary Conference*, Orlando, Florida, January 9-13, 1999.
23. **Henry CJ**, McCaw DL, Tate DJ, Stoker A, Tyler JW. The effect of chemotherapy on antibody titers to canine parvovirus and distemper virus. *Journal of Veterinary Internal Medicine* 1999;13:282.
24. Higginbotham ML, Luna LD, **Henry CJ**, Turnquist SE, Moore AS, Graham JC, Smith AN. Feline non-ocular melanoma: a retrospective study of 23 cases. *19<sup>th</sup> Veterinary Cancer Society Annual Conference*, Wood's Hole, MA, Nov 13-16, 1999:22.
25. Moore AS, Kintzer P, Ogilvie GK, Brewer WG, Burke C, Fischer J, **Henry C**, Kitchell BE, Kristal O, Sheafor S, Williams LE. A diuresis protocol for streptozotocin in dogs with pancreatic islet cell tumors. *19<sup>th</sup> Veterinary Cancer Society Annual Conference*, Wood's Hole, MA, Nov 13-16, 1999:69.
26. Milner RJ, **Henry CJ**, Lattimer JC, Dormehl I, Louw WKA. Targeted radiotherapy of canine multilobular osteochondroma in 3 cases using Sm-153-EDTMP. *19<sup>th</sup> Veterinary Cancer Society Annual Conference*, Wood's Hole, MA, Nov 13-16, 1999:63.

**Scientific Abstracts/ Proceedings (cont'd):**

27. **Henry CJ**, Steele JK, McCaw DL, Buss MS, Pope ER, Tyler JW. Clinical assessment of chemosensitivity testing for treatment planning for dogs with malignant neoplasia. 19<sup>th</sup> *Veterinary Cancer Society Annual Conference*, Wood's Hole, MA, Nov 13-16, 1999:10.
28. Fox DB, Cook JL, Kreeger JM, **Henry CJ**. Canine synovial sarcoma: A retrospective assessment of described prognostic criteria in 16 cases (1994-1999). Phi Zeta Research Day, University of Missouri, Columbia, MO, April 7, 2000
29. Milner RJ, **Henry CJ**, Lattimer JC, Dormehl IC, Louw WKA, Kilian E. Targeted radiotherapy of canine multilobular osteochondroma in 3 cases using Sm-153-EDTMP. European Association of Nuclear Medicine Congress, Paris, France, September 2-6, 2000.
30. McCaw DL, Suedmeyer WK, **Henry CJ**, Tate DJ. Photodynamic therapy treatment of avian neoplasms. 20<sup>th</sup> *Veterinary Cancer Society Annual Conference*, Asilomar, CA, October 15-18, 2000: 88.
31. **Henry CJ**, McCaw DL, Higginbotham ML, Brock KV, Tyler JW. The effect of chemotherapy on antiviral antibody titers in dogs with lymphoma. 20<sup>th</sup> *Veterinary Cancer Society Annual Conference*, Asilomar, CA, October 15-18, 2000;82.
32. Higginbotham ML, **Henry CJ**, Watson Z, Turnquist SE, Rassnick K, Chun R. Biological behavior of canine aural mast cell tumors. 20<sup>th</sup> *Veterinary Cancer Society Annual Conference*, Asilomar, CA, October 15-18, 2000:52.
33. Johannes CM, **Henry CJ**, Hamilton T, Smith AN, Turnquist AN. Feline hemangiosarcoma: a retrospective study of 36 cases. 20<sup>th</sup> *Veterinary Cancer Society Annual Conference*, Asilomar, CA, October 15-18, 2000:53.
34. **Henry CJ**, Kreeger JM, Jones BD. Comparison of three biopsy instruments for obtaining diagnostic percutaneous renal biopsy samples. 20<sup>th</sup> *Veterinary Cancer Society Annual Conference*, Asilomar, CA, October 15-18, 2000:81.
35. **Henry CJ**, McCaw DL, Tate DJ, Bravo L, Sheafor S, Chun R, Turnquist SE. Preliminary results of a VCOG trial of mitoxantrone and piroxicam for treatment of canine transitional cell carcinoma. 20<sup>th</sup> *Veterinary Cancer Society Annual Conference*, Asilomar, CA, October 15-18, 2000:29.
36. Johannes CM, **Henry CJ**, Turnquist SE, Hamilton T, Smith AN. Feline hemangiosarcoma: a retrospective study of 42 cases; Phi Zeta Research Day, University of Missouri, May 4, 2001.
37. Higginbotham ML, **Henry CJ**. Assessment of in vitro antineoplastic activity of MU-Gold. Phi Zeta Research Day, University of Missouri, May 4, 2001; **2<sup>nd</sup> place award winner**.
38. ML Higginbotham, **CJ Henry**, KV Katti, JK Schwarz, SW Casteel. Assessment of in vivo pharmacokinetics and in vitro cytotoxicity of MU-Gold. 21<sup>st</sup> *Veterinary Cancer Society Annual Conference*, Baton Rouge, LA, October 11-14, 2001;22.
39. LE Russell, S Steinberg, **CJ Henry**. The current state of animal tumor registries. 21<sup>st</sup> *Veterinary Cancer Society Annual Conference*, Baton Rouge, LA, October 11-14, 2001:61.

**Scientific Abstracts/ Proceedings (cont'd):**

40. **CJ Henry**, JC Lattimer, JW Tyler, DL McCaw, ML Higginbotham. Effect of external beam radiation on hematological responses to <sup>153</sup>Sm-EDTMP in tumor-bearing dogs. 21<sup>st</sup> *Veterinary Cancer Society Annual Conference*, Baton Rouge, LA, October 11-14, 2001:50.
41. MR Lewis, **CJ Henry**, J Zhang, CB Siegall. Radiolabeling of SGN-10 and cBR96 for imaging and therapy of canine carcinomas. 21<sup>st</sup> *Veterinary Cancer Society Annual Conference*, Baton Rouge, LA, October 11-14, 2001:80.
42. Higginbotham ML, Lattimer JC, **Henry CJ**, Tyler JW, McCaw DL, Dodam G. Retrospective evaluation of canine nasal adenocarcinomas treated with radiation via linear accelerator. 21<sup>st</sup> *Veterinary Cancer Society Annual Conference*, Baton Rouge, LA, October 11-14, 2001:78.
43. Chun R, Garrett LD, **Henry C**, Wall M, Smith A. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. 21<sup>st</sup> *Veterinary Cancer Society Annual Conference*, Baton Rouge, LA, October 11-14, 2001:7.
44. **CJ Henry**, WG Brewer, Jr., EM Whitley, JW Tyler, GK Ogilvie, A Norris, LE Fox, WB Morrison, A Hammer, DM Vail, J Berg. Canine digital tumors: Retrospective review of 63 cases. 21<sup>st</sup> *Veterinary Cancer Society Annual Conference*, Baton Rouge, LA, October 11-14, 2001; 3.
45. MR Lewis, **CJ Henry**, J Zhang, CB Siegall. Radiolabeling of SGN-10 and cBR96 for imaging and therapy of canine carcinomas.[poster] Molecular Biology Week, University of Missouri-Columbia, March 4-9, 2002.
46. **CJ Henry**, JW Tyler, MC McEntee, T Stokol, KS Rogers, R Chun, LD Garrett, DL McCaw, ML Higginbotham. Evaluation of the V-BTA urine test for detection of canine transitional cell carcinoma. [poster] 2002 ACVIM Annual Forum, Dallas, Texas, May 29-June 1, 2002.
47. RJ Milner, **C Henry**, IC Dormehl, WK Louw, E Kilian. Samarium-153-EDTMP targeted radiotherapy and carboplatin radiosensitization in naturally-occurring canine osteosarcoma. [poster] 2002 ACVIM Annual Forum, Dallas, Texas, May 29-June 1, 2002.
48. Porock D, Stoll M, Higginbotham M, **Henry CJ**. The effects of altered time intervals between surgery and radiation therapy on wound healing. 12<sup>th</sup> International Conference on Cancer Nursing, London, England, August 28-September 1, 2002; [oral]
49. **Henry CJ**, Selting K, Turnquist SE, Kuntz JK, Melcon DK, Chun R, Hackner SG, Goehl SG.. Canine primary skeletal hemangiosarcoma: 17 cases. 22<sup>nd</sup> Annual Conference of the Veterinary Cancer Society; New York, New York, Sept 12-15, 2002; 4.
50. Bryan J, Jackson T, **Henry CJ**, Allen T, Jones R, Simcik C, Slawienski MJ, Steinberg HS. Canine renal neoplasms: A retrospective of 30 cases. 22<sup>nd</sup> Annual Conference of the Veterinary Cancer Society; New York, New York, Sept 12-15, 2002;26.
51. KD Johnson, **CJ Henry**, GV Glinsky, A Raz, VV Glinsky. The Anti-Galectin-3 compounds lactulosyl-L-leucine and modified citrus pectin enhance cytotoxicity of doxorubicin against a murine hemangiosarcoma cell line. 23<sup>rd</sup> Annual Conference of the Veterinary Cancer Society Annual Conference, Madison, Wisconsin, September 26-29, 2003;56 [oral]

**Scientific Abstracts/ Proceedings (cont'd):**

52. JN Bryan, MR Lewis, **CJ Henry**, NK Owen, CB Siegall, CJ Anderson. Copper-64-labeled antibodies for radioimmunotherapy of cancer. 23<sup>rd</sup> Annual Conference of the Veterinary Cancer Society Annual Conference, Madison, Wisconsin, September 26-29, 2003;6; *MacEwen Memorial Award winner for Outstanding Basic Research*. [oral]
53. ML Higginbotham, **CJ Henry**, DL McCaw, LR Russell, SW Casteel, KV Katti Phase I clinical trial evaluating MU-Gold in lymphoma bearing dogs. 23<sup>rd</sup> Annual Conference of the Veterinary Cancer Society Annual Conference, Madison, Wisconsin, September 26-29, 2003;58. [oral]
54. **CJ Henry**, MR Stoll, ML Higginbotham, SE Turnquist, JC Lattimer, JW Tyler, D Porock, DA Kunz. Effect of timing of radiation initiation on post-surgical wound healing in dogs. 23<sup>rd</sup> Annual Conference of the Veterinary Cancer Society Annual Conference, Madison, Wisconsin, September 26-29, 2003;52. [oral]
55. Bryan JN, Mohsin H, Jia F, Sivaguru G, Siegall CB, Anderson CJ, Miller WH, **Henry CJ**, and Lewis MR. Biodistributions and tumor dosimetry of copper-64-labeled DOTA-cBR96 and DOTA-cT84.66 in xenograft-bearing mice. Missouri Life Sciences Week, April 2004.
56. Johnson K, **Henry CJ**, Glinsky G, Turk J, Raz, A, Glinsky V. Additive anti-tumor effects of anti-galectin-3 compounds lactulosyl-L-Leucine and modified citrus pectin with doxorubicin against a murine hemangiosarcoma cell line. 27<sup>th</sup> Annual Phi Zeta Day, University of Missouri, Columbia, MO, April 23, 2004; *first place award winner in Interns, 1<sup>st</sup> year residents, and graduate students category*.
57. Bryan J, Lewis M, Mohsin H, Jia F, Sivaguru G, Siegall CB, Anderson CJ, Miller WH, **Henry CJ**. Biodistributions and tumor dosimetry of copper-64-labeled DOTA-cBR96 and DOTA-CT84.66 in xenograft-bearing mice. 27<sup>th</sup> Annual Phi Zeta Day, University of Missouri April 23, 2004; *first place award winner in 2<sup>nd</sup> and 3<sup>rd</sup> year residents, and graduate students category*.
58. JN Bryan, MR Lewis, **CJ Henry**, NK Owen, CB Siegall, CJ Anderson. Copper-64-labeled antibodies for radioimmunotherapy of cancer. 22nd Annual ACVIM Forum, Minneapolis, MN, June 9-12, 2004; 209. [oral]
59. Suedmeyer WK, **Henry C**, McCaw D, Boucher M. Use of photodynamic therapy against squamous cell carcinoma in a rose-ringed parakeet (*Psittacula krameri*). 2004 Proceedings of the AAZV, AAWV, WDA Joint Conference; 262.
60. Johnson KD, Turk JR, Glinsky GV, **Henry CJ**, Raz A, Glinsky VV. Immunohistochemical confirmation of the Galectin-3 target in murine and canine hemangiosarcoma cell. 24<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Kansas City, MO, Nov 3-6, 2004; 32. [oral]
61. Bryan JN, Jia F, Mohsin H, Sivaguru G, Siegall CB, Anderson CJ, **Henry CJ**, Lewis MR. Comparison of internalizing and non-internalizing monoclonal antibodies for copper-64 radioimmunotherapy in mice bearing colon cancer xenografts. 24<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Kansas City, MO, Nov 3-6, 2004; 33. [oral]
62. **Henry CJ**, Hahn AW, Tyler JW, Steinberg HS, Caldwell CW. Comparative oncology solution to understanding hormonal impact in the epidemiology of lymphoma. 24<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Kansas City, MO, Nov 3-6, 2004; 85. [poster]

**Scientific Abstracts/ Proceedings (cont'd):**



63. McCoig AM, **Henry CJ**, Milner RJ, Kunz DA, Tyler JW, McCaw DL, Bryan JN. Use of samarium-153-EDTMP for the treatment of 21 dogs with primary tumors of the skull. 24<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Kansas City, MO, Nov 3-6, 2004; 92. [poster]
64. **Henry CJ**, Turnquist SE, Beissenherz ME, Rankin WV, Tyler JW, Hargrove D. Evaluation of survivin as a molecular marker of canine bladder cancer and pilot assessment of its prognostic significance. 24<sup>th</sup> Annual Conference of the VCS, Kansas City, MO, Nov 3-6, 2004;99. [poster]
65. Selting KA, **Henry CJ**, Turnquist SE, Katti KV, Raghuraman K, Turk JR, Gustafson DL, Hargrove D, Garro M, Tyler JW. Preliminary evaluation of the novel antioxidant THP-AI in the prevention of tissue necrosis following doxorubicin after extravasation. 24<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Kansas City, MO, Nov 3-6, 2004;102. [poster]
66. Bryan, JN, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, **Henry CJ**, Lewis MR. Comparison of high resolution mouse PET/CT imaging and conventional biodistributions of copper-64-labeled antibodies. Missouri Life Sciences Week, April 2005. ***First Place in the Technology Development***
67. **Henry CJ**, Lattimer JL, Milner RJ, Tyler JW, McCaw DL, Selting KA, Bryan JN, Johnson KD, Higginbotham ML, Kunz DA, Garro M, Harbke LM. Effect of carboplatin administration on bone uptake of samarium-153-EDTMP in dogs with osteosarcoma. Proceedings of the 25<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Huntington Beach, California October 20-23, 2005:66.
68. Johnson KD, **Henry CJ**, Tyler JW, Moses EM, Hahn AW. Spontaneously arising neoplasia in juvenile dogs (1980-2000). Proceedings of the 25<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Huntington Beach, California October 20-23, 2005:11.
69. Rankin WV, **Henry CJ**, Rucker EB, Luth JA, Turnquist SE, Beissenherz ME, Tyler JW, Turk JR, Knapp DW. Identification of surviving subcellular localization and of novel splice variants in canine urinary bladder tumors. Proceedings of the 25<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Huntington Beach, California October 20-23, 2005:37, ***MacEwen Memorial Award winner for Outstanding Basic Research.***[oral]
70. Bryan JN, **Henry CJ**, Hahn AW, Caldwell CW. A population study of neutering status as a risk factor for canine prostate cancer. Proceedings of the 25<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Huntington Beach, California October 20-23, 2005:95.
71. **Henry CJ**. Radiopharmaceutical Treatment of Canine Osteosarcoma. Proceedings of the 2006 Veterinary Cancer Society Symposium on Osteosarcoma, Sedona, AZ March 5-8, 2006:50-52.
72. **Henry CJ**. Carboplatin and Samarium-153-EDTMP combination therapy for canine osteosarcoma. Proceedings of the 2006 ACVIM Forum, Louisville, KY, May 31-June 2, 2006:375-377.
73. Bryan JN, Taylor KH, **Henry CJ**, Selting KA, Lewis MR, McCaw DL, Johnson KD, Rankin WV, Caldwell CW. Comparative epigenetics of a tumor suppressor gene in canine lymphomas. Proceedings of the 26<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Callaway Gardens, GA, October 19-22, 2006.

**Scientific Abstracts/ Proceedings (cont'd):**

74. **Henry CJ**, Downing S, Rosenthal RC, Klein MK, Meleo K, Wheeler L, Fredericks J, Villamil JA, Fineman LS, McCaw DL, Northrup NC, Higginbotham ML, McMichael J. Clinical comparison of LDI-100, a preparation containing human chorionic gonadotropin and Bacillus Calmette-Guerin, to single-agent vinblastine for the treatment of canine mast cell tumors. Proceedings of the 26<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Callaway Gardens, GA, October 19-22, 2006.
75. Villamil JA, Bryan JN, Tyler JW, Keeler MR, **Henry CJ**, McCaw DL. Use of the Veterinary Medical Database to update epidemiological data in the veterinary oncology literature. Proceedings of the 26<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Callaway Gardens, GA, October 19-22, 2006. **RS Brodey Memorial Award Winner for Outstanding Clinical Research [oral]**
76. **Henry CJ**, Higginbotham ML, Rodriguez CO, Downing S, Rosenberg M, Tyler JW, Fox LE, McCaw DL, Selting KA, Bryan JN, Johnson KD, Beittenmiller MR. Prospective evaluation of doxorubicin vs. mitoxantrone for adjuvant therapy of feline mammary carcinoma. Proceedings of the 26<sup>th</sup> Annual Conference of the Veterinary Cancer Society, Callaway Gardens, GA, October 19-22, 2006.
77. Cutler CS, Bryan JN, Chandia M, Irwin DJ, Engelbrecht HP, Rold T, Lattimer J, Hoffman T, **Henry CJ**, Ketring AR. Evaluation of <sup>177</sup>Lu labeled DOTMP and EDTMP. 17th International Symposium on Radiopharmaceutical Sciences, Aachen, Germany April, 2007.
78. Selting K, Waldrep J, Reiner C, Mercier E, Branson K, Kim D, **Henry C**, Owen N, Gustafson D, Madsen R, Dhand R. Clinico-pathologic findings after targeted inhaled chemotherapy in dogs. Am Thoracic Society Int'l Conf, San Francisco, CA, May 18-23, 2007
79. Waldrep J, Selting K, Reiner C, Mercier E, Branson K, Kim D, **Henry C**, Owen N, Gustafson D, Hoopes P, Madsen R, Dhand R. Targeted pulmonary delivery of chemotherapy with the AeroProbe Intracorporeal Nebulizing Catheter (INC). American Thoracic Society International Conference, San Francisco, CA, May 18-23, 2007
80. Villamil JA, **Henry CJ** (faculty sponsor) Use of the Veterinary Medical Database to update epidemiological data in the veterinary oncology literature. Phi Zeta Research Day, University of Missouri-Columbia, March 23, 2007.
81. Johnson KD, **Henry CJ** (faculty sponsor) Prospective evaluation of doxorubicin vs. mitoxantrone for adjuvant therapy of feline mammary carcinoma. Phi Zeta Research Day, University of Missouri-Columbia, March 23, 2007; **4<sup>th</sup> place award winner, Advanced Graduate Students and Post-docs.**
82. Paoloni M, Tandle A, Mazcko C, LeBlanc A, Vail D, **Henry C**, Sorenmo K, Hanna E, Libutti S, Khanna C. The Comparative Oncology Trials Consortium: Evaluation of RGD targeted delivery of phage expressing TNF- $\alpha$  to tumor bearing dogs. American Assoc for Cancer Research Annual Meeting April 14-18, 2007, abstract # 2225 [poster]
83. Waldrep JC, Selting KA, Mercier E, Branson K, Kim DY, **Henry CJ**, Owen N, Gustafson D, Madsen R, Dhand R. Could inhaled chemotherapy be targeted to a specific lung lobe? American Thoracic Society International Conference, San Francisco, CA, May 2007 (poster).
84. Selting KA, Waldrep JC, Reiner C, Mercier E, Branson K, Kim DY, **Henry CJ**, Owen N, Gustafson D, Madsen R, Dhand R. Clinico-pathologic findings after targeted inhaled chemotherapy in dogs. American Thoracic Society International Conference, San Francisco, May 2007 (poster).

**Scientific Abstracts/ Proceedings (cont'd):**

85. Villamil JA, **Henry CJ**, Hahn AW, Tyler JW. Update on canine skin tumors epidemiological data using the veterinary medical database. Proceedings of the Veterinary Cancer Society Annual Conference, Fort Lauderdale, FL, November 1 – 4, 2007:24.
86. Knapp DW, **Henry CJ**, Widmer WR, Ramos-Vara JA, Lucroy MD, Alva R, Hanson PD, Abbo A, Bonney PL. Phase III Clinical trial of cisplatin vs firocoxib vs cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. Proceedings of the Veterinary Cancer Society Annual Conference, Fort Lauderdale, FL, November 1 – 4, 2007:68.
87. Rankin WV, **Henry C**, Green J, Turnquist W, Beissenherz M, Tyler J, Turk J. Evaluation of survivin in canine urinary bladder cystitis. Proceedings of the Veterinary Cancer Society Annual Conference, Fort Lauderdale, FL, November 1 – 4, 2007:21.
88. **Henry CJ**, Hematological impact of administering Samarium-153-EDTMP with or without concurrent carboplatin to dogs with appendicular osteosarcoma. Proceedings of the Veterinary Cancer Society Annual Conf, Fort Lauderdale, FL, November 1 – 4, 2007:56.
89. Bommarito DA, Bryan JN, Cutler CS, Lattimer JC, Ketring KA, **Henry CJ**. Systemic toxicity of Lu-177-DOTMP administered intravenously to normal dogs. Proceedings of the Veterinary Cancer Society Annual Conference, Fort Lauderdale, FL, November 1 – 4, 2007:27.
90. Risetto K, Villamil J, Selting K, **Henry C**. The evolution and recent trends in incidence of feline intestinal neoplasia. Proceedings of the Veterinary Cancer Society Annual Conference, Fort Lauderdale, FL, November 1 – 4, 2007:40.[poster]
91. Selting K, Waldrep J, Reinero C, Branson K, Kim D, **Henry C**, Owen N, Dhand R. Tolerability of Targeted Inhaled Combined Chemotherapy in Dog, National VA Research Week, Harry S. Truman Veteran's Administration Hospital, May 11-17, 2008.
92. **Henry C J**. Veterinary Oncology Screening Tests and Biomarkers—Where's the Evidence? 2009 American College of Veterinary Internal Medicine Annual Forum, Montreal, Quebec, June, 2009
93. **Henry C**. Clinical application of veterinary cancer biomarkers. Biomarkers in Veterinary Medicine Conference, BioCity, Nottingham, UK, July 8 – 9, 2009.
94. **Henry CJ**, Parker A, Zhao M, Selting K, Axiak S, Hausheer F. Effect of the novel chemoprotectant drug, Tavocept™ on *in vitro* cytotoxicity of cisplatin and cisplatin/piroxicam combination therapy against canine transitional cell carcinoma of the bladder. Proceedings of the Veterinary Cancer Society Annual Conference, Austin, TX, Oct 17 – 19, 2009,84.
95. Selting KA, Decedue CJ, **Henry CJ**, Axiak S, Tate D, Bilof KJ, Kim DY. Dose escalation safety study of Nanotax® in dogs. Kansas City Area Life Sciences Institute Summit; March 8 – 9, 2010
96. **Henry CJ**. Use of spontaneously arising canine TCC as a relevant model of late-stage human bladder cancer in which to assess the novel drug, Tavocept™, for ability to mitigate toxicity and improve efficacy of a cisplatin and piroxicam combination therapy protocol, 3<sup>rd</sup> International Conference on Drug Discovery and Therapy; Dubai. UAE, February 2011.
97. Axiak SM, Lattimer J, Selting K, **Henry CJ**, Bryan JN, Cutler C, Katti K, Upendran A, Kannan R. Phase I Clinical Trial of Intratumorally Administered Radioactive Gold Nanoparticles in Canine Prostatic Carcinoma. World Veterinary Cancer Meeting, Paris, France, March 2012.

**Scientific Abstracts/ Proceedings (cont'd):**

98. **Henry CJ**, Selting KA, Axiak, SM, Bryan JN, Tate DJ, Hausheer F. The novel chemoprotectant drug, Tavocept™, facilitates a shortened cisplatin infusion for treatment of cancer-bearing dogs. World Veterinary Cancer Meeting, Paris, France, March 2012.
99. Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, Bryan JN, **Henry CJ**, Tate DJ, Bryan ME, Katti KV, Kannan R. Phase 1 Trial of Radioactive Gold Nanoparticle Therapy in Dogs with Naturally Occurring Prostate Cancer. Mizzou Advantage Day, University of Missouri, April 30, 2013.
100. Bryan JN, D Tate, S Cai, L Forrest, KA Selting, B Flesner, SM Axiak-Bechtel, **CJ Henry**, M Cohen. Phase I/II Evaluation of Cisplatin Hyaluronan Nanoparticles in Tumor-Bearing Dogs. Mizzou Advantage Day, University of Missouri, April 30, 2013.
101. Bryan JN, D Tate, A Glahn, B Fowler, B Flesner, K Fitzpatrick, C Herrera, L Donnelly, SM Axiak-Bechtel, KA Selting, **CJ Henry**. Comparative Veterinary Clinical Trial of Artesunate or Placebo with Doxorubicin for Lymphoma in Dogs as Preclinical Evidence of Efficacy. Mizzou Advantage Day, University of Missouri, April 30, 2013.
102. Selting KA, Axiak SM, Bryan JN, Decedue C, **Henry CJ**. Phase I/II Clinical Trial of CTI52010 in Tumor-Bearing Dogs. World Veterinary Cancer Meeting, Paris, France, March 2012. Henry CJ, Tate DJ, Selting KA, Bryan JN, Axiak-Bechtel S, Hausheer F. Evaluation of Tavocept, Piroxicam and Cisplatin for the Treatment of Canine Transitional Cell Carcinoma of the Urinary Bladder. American College of Veterinary Internal Medicine Forum; Seattle, WA, June 2013 (late-breaking research; 20 min abstract)
103. Herrera C, Tate D, Maitz C, Axiak-Bechtel SA, Avenell J, Lunceford,, **Henry CJ**, Selting KA, Flesner B, Donnelly L, Fowler B, Glahn A, Collins A, Varterasian M, Tung D, Roix J, Zhang L, Saha S, Bryan JN. Hypermetabolic tumor volume can be calculate from PET/CT imaging for response definition. 33rd Annual Conference Proceedings of the Veterinary Cancer Society, Minneapolis, MN, October 2013.
104. Selting KA, Bechtel SM, Decedue C, **Henry CJ**, Bryan JN. Pharmacokinetics of Crititax®, a novel nanoparticle formulation of paclitaxel, in tumor-bearing dogs. 33rd Annual Conference Proceedings of the Veterinary Cancer Society, Minneapolis, MN, October 2013.
105. Tate D, Maitz C, Axiak-Bechtel S, Avenell J, Lunceford J, **Henry C**, et al. Bryan J Cu-64-ATSM PET scanning predicts degree and location of tumor hypoxia in dogs for hypoxia-directed therapy. Veterinary Cancer Society Annual Conference; Minneapolis, MN, October 2013 (oral abstract)
106. **Henry CJ**, Kumar SR, May TJ, Bryan JN, Eaton AM. Characterization of decorin and programmed death ligand-1 expression supports the role of canine urothelial transitional cell carcinoma as a model of human bladder cancer. Veterinary Cancer Society Annual Conference; Virginia, October 2015
107. Kumar SR, May TJ, **Henry CJ**, Bryan JN, Eaton AM. Evaluation of programmed death ligand gene and protein expression in canine hematologic malignant cells. Veterinary Cancer Society Annual Conference; Virginia, October 2015.
108. Flesner BK, Tate DJ, Bechtel SM, Bryan JN, Selting KA, **Henry CJ**. Tavocept Enables a Shortened Diuresis Protocol for Dogs with Appendicular Osteosarcoma Receiving Cisplatin. Veterinary Cancer Society Annual Conference; Orlando, FL October 2016

### **Invited Presentations since 2000:**

1. "Top ten oncology tips for the new millennium" Greater St. Louis Veterinary Medical Association Meeting, St. Louis, MO, January 7, 2000.
2. "Practice Tip-Venous Access Ports" Western Veterinary Conference, Las Vegas, Nevada, February 23, 2000.
3. "Chemotherapy Safety" Western Veterinary Conference, Las Vegas, Nevada, February 23, 2000.
4. "Mast Cell Neoplasia in Small Animals" Western Veterinary Conference, Las Vegas, Nevada, February 24, 2000.
5. "Soft Tissue Sarcomas in the Dog and Cat" Western Veterinary Conference, Las Vegas, Nevada, February 24, 2000.
6. "Recent Advances in Clinical Oncology" Western Veterinary Conference, Las Vegas, Nevada, February 24, 2000.
7. "Oncologic Emergencies" Western Veterinary Conference, Las Vegas, Nevada, February 24, 2000.
8. "Incidence and therapy of cancer in companion animals", Pfizer Expert Panel Meeting, New London, CT, August 25, 2000.
9. "Managing Canine Mast Cell Tumors", South African Veterinary Association Congress 2000, Durban, South Africa, September 19-21, 2000.
10. "Oncologic Emergencies". South African Veterinary Association Congress 2000, Durban, South Africa, September 19-21, 2000.
11. "Canine Oral Melanoma: A Comparative Oncology Approach". South African Veterinary Association Congress 2000, Durban, South Africa, September 19-21, 2000.
12. "Oral Neoplasia". Auburn University College of Veterinary Medicine 93<sup>rd</sup> Annual Conference, Auburn, Alabama, November 3-5, 2000. 1 hour
13. "Update on Mast Cell Tumors". Auburn University College of Veterinary Medicine 93<sup>rd</sup> Annual Conference, Auburn, Alabama, November 3-5, 2000. 1 hour
14. "Safety Issues in Handling Chemotherapeutics". Auburn University College of Veterinary Medicine 93<sup>rd</sup> Annual Conference, Auburn, Alabama, November 3-5, 2000. 1 hour
15. "Current trends in the treatment of transitional cell carcinoma of the bladder" North American Veterinary Conference, Orlando, Florida, January 13-19, 2001, 1 hour.
16. "Prognostic factors in veterinary oncology" North American Veterinary Conference, Orlando, Florida, January 13-19, 2001, 1 hour.
17. "Oral tumors in dogs and cats" NAVC, Orlando, Florida, January 13-19, 2001, 1 hour

**Invited Presentations since 2000 (cont'd):**

18. "Vascular access ports-indications and considerations" NAVC, Orlando, Florida, Jan 13-19, 2001, ½ hour.
19. "Clinical applications for fine needle aspiration"; Veterinary Technician's Conference; St. Louis University, St. Louis, MO; April 5, 2001; 1 hour.
20. "Current Diagnostic and Therapeutic Approach to Canine Transitional Cell Carcinoma of the Bladder." 19<sup>th</sup> Annual Forum of the ACVIM, Denver, Colorado, May 22-25, 2001- 1 hour.
21. "Current recommendations for managing vaccine-associated feline sarcomas." 2002 Annual Convention, MO Veterinary Medical Association, Lake Ozark, MO, January 17-20, 2002, 1 hour.
22. "The role of man's best friend in development of novel radiopharmaceutical agents" 2002 MURR Research Day, Columbia, MO, May 3, 2002, ½ hour.
23. "Early Bird CE: Management of Oral Tumors." 139<sup>th</sup> AVMA Annual Convention. Nashville, TN, July 13-17, 2002.
24. "Prognostic Factors in Veterinary Oncology." 139<sup>th</sup> AVMA Annual Convention. Nashville, TN, July 13-17, 2002.
25. "What's New for Mast Cell Tumors?" 139<sup>th</sup> AVMA Annual Convention. Nashville, TN, July 13-17, 2002.
26. "What's New in the Diagnosis and Treatment of TCC of the Bladder?" 139<sup>th</sup> AVMA Annual Convention. Nashville, TN, July 13-17, 2002.
27. "Managing primary bone tumors in dogs" Central Veterinary Conference. Kansas City, MO. August 17-20, 2002.
28. "Commonly asked questions in veterinary oncology and chemotherapy safety" Central Veterinary Conference. Kansas City, MO. August 17-20, 2002.
29. "Canine bladder cancer- The latest update." Central Veterinary Conference. Kansas City, MO. August 17-20, 2002.
30. "What's new in treating mast cell tumors?" Central Veterinary Conference. Kansas City, MO. August 17-20, 2002.
31. "Prognostic factors in veterinary oncology." Central Veterinary Conference. Kansas City, MO. August 17-20, 2002.
32. "Oncologic emergencies." Central Veterinary Conference. Kansas City, MO. August 17-20, 2002.
33. "Why cats are not small dogs when it comes to veterinary oncology." Central Veterinary Conference. Kansas City, MO. August 17-20, 2002.
34. "Onco-Logical Approach to Chemotherapy." Tufts Animal Expo, Boston, MA. September 12-15, 2002.

**Invited Presentations since 2000 (cont'd):**

35. "Prognostic factors in veterinary oncology." Tufts Animal Expo, Boston, MA. September 12-15, 2002.
36. "Canine bladder cancer- The latest update." Tufts Animal Expo, Boston, MA. September 12-15, 2002.
37. "Clinical use of radiopharmaceuticals in veterinary oncology." 27<sup>th</sup> Annual ACVIM Forum, Charlotte, NC. June 4 –8, 2003.
38. "All creatures great and small with cancer: An introduction to veterinary and comparative oncology." Life Sciences Summer Undergraduate Researcher Opportunity Program (LSUROP) Series; University of Missouri, Columbia, MO. July 2, 2003.
39. "Prognostic factors in veterinary oncology." 140<sup>th</sup> AVMA Annual Convention. Denver, CO, July 19-23, 2003.
40. "Oncology in the emergency room Part I: structural and metabolic emergencies." 140<sup>th</sup> AVMA Annual Convention. Denver, CO, July 19-23, 2003.
41. "Oncology in the emergency room Part II: tumor and treatment related emergencies." 140<sup>th</sup> AVMA Annual Convention. Denver, CO, July 19-23, 2003.
42. "Practical use of radiopharmaceuticals in veterinary oncology." 140<sup>th</sup> AVMA Annual Convention. Denver, CO, July 19-23, 2003.
43. "Canine and feline respiratory tract tumors from planum to pleura." 140<sup>th</sup> AVMA Annual Convention. Denver, CO, July 19-23, 2003.
44. "Canine bladder cancer" 76<sup>th</sup> Western States Veterinary Conference. Las Vegas, NV, February 16, 2004, 1 hour.
45. "Osteosarcoma Options: What's Best & When?" 76<sup>th</sup> Western States Veterinary Conference. Las Vegas, NV, February 16, 2004, 1 hour.
46. "Oncological Approach to Cancer Care and Client Communications I" 76<sup>th</sup> Western States Veterinary Conference. Las Vegas, NV, February 16, 2004, 1 hour.
47. "Oncological Approach to Cancer Care and Client Communications II" 76<sup>th</sup> Western States Veterinary Conference. Las Vegas, NV, February 16, 2004, 1 hour.
48. "Oral Tumors" Music City Veterinary Conference, Tennessee VMA. Franklin, TN, March 7, 2004, 1.5 hours.
49. "Respiratory Tract Tumors" Music City Veterinary Conference, Tennessee VMA. Franklin, TN, March 7, 2004, 1.5 hours.
50. "Prognostic Factors in Veterinary Oncology" Music City Veterinary Conference, Tennessee VMA. Franklin, TN, March 7, 2004, 1.5 hours.
51. "Canine Mast Cell Tumors" Music City Veterinary Conference, Tennessee VMA. Franklin, TN, March 7, 2004, 1.5 hours.

**Invited Presentations since 2000 (cont'd):**

52. "Oral Malignancies in Dogs and Cats" ACVIM Forum Focus, Minneapolis, MN, June 9, 2004. 45 minutes.
53. "Going Out on a Limb- Approach to Canine Osteosarcoma" ACVIM Forum Focus, Minneapolis, MN, June 9, 2004. 45 minutes.
54. "A Planum to Pleura Review of Canine and Feline Respiratory Tract Tumors" ACVIM Forum Focus, Minneapolis, MN, June 9, 2004. 45 minutes.
55. "Controversies and clarifications regarding the diagnosis and treatment of canine bladder cancer" ACVIM Forum Focus, Minneapolis, MN, June 9, 2004. 45 minutes.
56. "Giving more than lip service to oral cancer in dogs and cats" Central New York Veterinary Academy Meeting, Rochester, NY, October 21, 2004. 1 hour.
57. "Going Out on a Limb- Approach to Canine Osteosarcoma" Central New York Veterinary Academy Meeting, Rochester, NY, October 21, 2004. 1 hour.
58. "A Planum to Pleura Review of Canine and Feline Respiratory Tract Tumors" Central New York Veterinary Academy Meeting, Rochester, NY, October 21, 2004. 1 hour.
59. "Controversies and clarifications regarding the diagnosis and treatment of canine bladder cancer" Central New York Veterinary Academy Meeting, Rochester, NY, October 21, 2004. 1 hour.
60. "Man's best friend in the fight against cancer" Science Teachers of Missouri Symposium, Columbia, MO, October 8, 2004; 1 hour.
61. "Updates and Controversies Regarding the Diagnosis and Treatment of Canine Bladder Cancer" 113<sup>th</sup> Annual Convention of the Missouri Veterinary Medical Association Meeting, Tan-Tar-A Resort, Lake of the Ozarks, Missouri, January 23, 2005; 50 minutes.
62. "Providing More than Lip Service for Dogs and Cats with Oral Malignancies" 113<sup>th</sup> Annual Convention of the Missouri Veterinary Medical Association Meeting, Tan-Tar-A Resort, Lake of the Ozarks, Missouri, January 23, 2005; 50 minutes.
63. "Going Out on a Limb- A Practical Approach to Canine Osteosarcoma" 113<sup>th</sup> Annual Convention of the Missouri Veterinary Medical Association Meeting, Tan-Tar-A Resort, Lake of the Ozarks, Missouri, January 23, 2005; 50 minutes.
64. "Advances from the Veterinary Cancer Society Meeting" 23<sup>rd</sup> Annual Forum of the American College of Veterinary Internal Medicine, Baltimore, MD, June 2, 2005; 50 minutes.
65. "Going to the Dogs: Comparative Oncology Redefined" Kansas City Area Life Sciences Research Day, Kansas City, MO, March 30, 2006; presentation and panel discussion.
66. "Advances from the Veterinary Cancer Society Meeting" 24<sup>th</sup> Annual Forum of the American College of Veterinary Internal Medicine, Louisville, KY, June 1, 2006; 50 minutes.
67. "Update on Canine Bladder Cancer- Must Trigones be Bygones?"; 2006 AVMA Convention, Honolulu, Hawaii, July 15, 90 minutes.
68. "Going Out On A Limb- The Latest in Staging and Treatment for Canine Osteosarcoma"; 2006 AVMA Convention, Honolulu, Hawaii, July 15, 90 minutes

**Invited Presentations since 2000 (cont'd):**



69. "Update on Canine Bladder Cancer- Must Trigones be Bygones?"; 2006 AVMA Convention Japanese Session, Honolulu, Hawaii, July 17, 2006, 3 hours.
70. "Going Out On A Limb- The Latest in Staging and Treatment for Canine Osteosarcoma"; 2006 AVMA Convention Japanese Session, Honolulu, Hawaii, July 17, 2006, 3 hours.
71. "Oncology Nursing Masterclass- Veterinary Cancer Care" 50<sup>th</sup> British Small Animal Veterinary Association Congress, Birmingham, England, April 12-15, 2007, 1.5 hours.
72. "Interactive Session- How do dogs and cats with cancer differ?" 50<sup>th</sup> British Small Animal Veterinary Association Congress, Birmingham, England, April 12-15, 2007, 1.5 hours.
73. "Going out on a limb: non-surgical and adjunctive treatments for osteosarcoma" 50<sup>th</sup> British Small Animal Veterinary Association Congress, Birmingham, England, April 12-15, 2007, 45 minutes
74. "Must trigones be bygones? An update on canine bladder neoplasia." 50<sup>th</sup> British Small Animal Veterinary Association Congress, Birmingham, England, April 12-15, 2007, 45 minutes.
75. "Oncology Erratum: An updated version of your veterinary school oncology notes. 25<sup>th</sup> American College of Veterinary Internal Medicine Forum, Seattle, WA, June 7, 2007, 50 minutes.
76. "Canine bladder cancer: Latest options for case management" 144<sup>th</sup> American Veterinary Medical Association Annual Convention, Washington, D.C., July 14-18, 2007, 90 minutes.
77. "Truth changes: An updated version of your veterinary school oncology notes. 144<sup>th</sup> American Veterinary Medical Association Annual Convention, Washington, D.C., July 14-18, 2007, 90 minutes.
78. "Transitional cell carcinomas." 32<sup>nd</sup> World Small Animal Veterinary Association Congress, Sydney, Australia, August 19-23, 2007, 1 hour.
79. "Prognostic factors in veterinary oncology." 32<sup>nd</sup> World Small Animal Veterinary Association Congress, Sydney, Australia, August 19-23, 2007, 1 hour.
80. "Oral Tumours." 32<sup>nd</sup> World Small Animal Veterinary Association Congress, Sydney, Australia, August 19-23, 2007, 1 hour.
81. "From top to bottom: Gastrointestinal tumours." 32<sup>nd</sup> World Small Animal Veterinary Association Congress, Sydney, Australia, August 19-23, 2007, 1 hour.
82. "Osteosarcoma in dogs." 32<sup>nd</sup> World Small Animal Veterinary Association Congress, Sydney, Australia, August 19-23, 2007, 1 hour.
83. "Keynote Address 2: Screening tests in cancer" 1<sup>st</sup> WorldVet Congress; combined meeting of the European Society of Veterinary Oncology and the Veterinary Cancer Society, Copenhagen, Denmark, February 28 – March 1, 2008, 30 minutes.
84. "Teaching Old Dogma New Tricks: Changes in Oncology Case Management Recommendations" 26<sup>th</sup> American College of Veterinary Internal Medicine Forum, San Antonio, TX, June 5, 2008, 50 minutes.
85. "Alimentary Education: An Oncologist's Short Course on GI Tumors" 26<sup>th</sup> American College of Veterinary Internal Medicine Forum, San Antonio, TX, June 7, 2008, 50 minutes.

**Invited Presentations since 2000 (cont'd):**

86. "Diagnostic and Therapeutic Advances in the Management of Canine Bladder Cancer" Ohio State University Royal Canin Symposium, Columbus, OH, Oct 4, 2008, 1 hour.
87. "Pfizer Veterinary Operations Oncology Training Day" Chicago, IL, November 4, 2008, 6 hours.
88. "Teaching Old Dogma New Tricks- Changes in Oncology Case Management Recommendations". Oklahoma Veterinary Medical Association Annual Conference, Oklahoma City, OK, January 30, 2009, 1 hour.
89. "Going Out on a Limb- Approach to Canine Osteosarcoma" Oklahoma Veterinary Medical Association Annual Conference, Oklahoma City, OK, January 30, 2009, 1 hour.
90. "New Hope in Prognostication and Eradication of Canine Mast Cell Tumors" Oklahoma Veterinary Medical Association Annual Conference, Oklahoma City, OK, January 30, 2009, 1 hour.
91. "Clinical Use of Palladia" Pfizer Webinar, Columbia, MO, June 16, 2009, 1 hour.
92. Keynote Address: "Clinical Application of Veterinary Cancer Biomarkers" Biomarkers in Veterinary Medicine Conference, BioCity, Nottingham, UK, July 8 – 9, 2009. 1 hour
93. "Onco-logical Approach to Case Management", NAHA Oncology Seminar Series, Fukuoku, Osaka, and Tokyo, Japan, September 2009, 8 hours.
94. "Diagnosis and Treatment Options for Oral Tumors in Dogs and Cats" NAHA Oncology Seminar Series, Fukuoku, Osaka, and Tokyo, Japan, September 2009, 8 hours.
95. "Canine and Feline Bladder Cancer Diagnosis and Treatment" NAHA Oncology Seminar Series, Fukuoku, Osaka, and Tokyo, Japan, September 2009, 8 hours.
96. "Canine Osteosarcoma Case Management" NAHA Oncology Seminar Series, Fukuoku, Osaka, and Tokyo, Japan, September 2009, 8 hours.
97. "How Dogs and Cats Differ When it Comes to Veterinary Oncology" NAHA Oncology Seminar Series, Tokyo, Japan, September 2009, 2 hours.
98. "Radiation Therapy Principles, Side Effects, and Case Examples" NAHA Oncology Seminar Series, Tokyo, Japan, September 2009, 2 hours.
99. "Navigating the Two-Way Street of Comparative Oncology", Oncology Grand Rounds, University of Missouri School of Medicine, Columbia, MO, Sept 15, 2009, 1 hour
100. "One Health, One Medicine: the Convergence of Human and Animal Health", MU Board of Curators Meeting, Columbia, MO October 22, 2009
101. "Navigating the Two-Way Street of Comparative Oncology", Chancellor's Breakfast, University of Missouri, Columbia, MO, November 3, 2009, 30 minutes.
102. "Transitional Cell Carcinoma of the Bladder: Must Trigones Be Bygones?" Western States Veterinary Conference, Las Vegas, NV, February 14 – 18, 2010, 1 hour.
103. "Teaching Old Dogma New Tricks: New Approaches to Old Oncology Problems" Western States Veterinary Conference, Las Vegas, NV, February 14 – 18, 2010, 1 hour.

**Invited Presentations since 2000 (cont'd):**

104. "A Life and Limb Approach to Treating Canine Osteosarcoma" Western States Veterinary Conference, Las Vegas, NV, February 14 – 18, 2010, 1 hour.
105. "Making the Grade in Case Management of Canine Mast Cell Tumors" Western States Veterinary Conference, Las Vegas, NV, February 14 – 18, 2010, 1 hour.
106. "Navigating the Two-Way Street of Comparative Oncology", Kansas City Area Life Sciences Institute Summit, Kansas City, MO, March 9, 2010, 20 minutes and panel discussion
107. "Oncology Erratum: A corrected version of your old oncology notes" North American Veterinary Conference, Orlando, FL, January 2011
108. "Update on Thyroid Carcinoma" North American Vet Conference, Orlando, FL, Jan 2011
109. "Veterinary Cancer Screening Tests- What's New and What's Useful?" North American Veterinary Conference, Orlando, FL, January 2011
110. "Veterinary Cancer Biomarkers- A Specifically Sensitive Topic, AAVCP Meeting; Baltimore, MD; November 2, 2010.
111. "One Health Initiative: Promoting Collaboration Between Human and Animal Health", World Animal Health Congress; Kansas City, MO; November 2011
112. "Teaching old dogma new tricks: New approaches to old oncology problems" AAHA Conference, Davenport, Iowa, November 2011
113. "A life and limb approach to treating canine osteosarcoma" AAHA Conference, Davenport, Iowa, November 2011
114. "An oncological approach to veterinary cancer care and client communication" AAHA Conference, Davenport, Iowa, November 2011
115. "Why cats are not small dogs when it comes to veterinary oncology" AAHA Conference, Davenport, Iowa, November 2011
116. "Taking aim at cancer: vaccine strategies, indications, and challenges" The Impact of 21st Century Vaccines on Global Health." Kansas City, MO, August 29, 2011
117. "Canine Bladder Cancer – Old Options with a New Twist" Southern European Veterinary Congress; Barcelona, Spain, October 16, 2012
118. "Staying Abreast of Mammary Cancer Treatment Options" Southern European Veterinary Congress; Barcelona, Spain, October 16, 2012 .
119. "Game Changers or Hype? – 5 New Cancer Treatments Reviewed" Southern European Veterinary Congress; Barcelona, Spain, October 19, 2012 .
120. "One Health/One Medicine – Academia/Industry Partnership" Potomac Valley Conference; May 14, 2013.
121. "One Health/One Medicine—One Combined R&D Strategy?" Informa R&D Congress, London, UK, May 2013; 50 minutes
122. "One Health / One Medicine--The next steps in enhancing collaboration with human health." Informa R&D: Veterinary Medicine-Vision to Product, Berlin, Germany, Feb 11, 2014; 35 min, with panel discussion after

**Invited Presentations since 2000 (cont'd):**

123. "Navigating the One Health Obstacle Course in an Academic Setting" American Association of Veterinary Medical Colleges Annual Conference; Alexandria, VA, March 14, 2014.
124. "Unleashing the Power of Comparative Oncology Models in Cancer Research" International Society for the Cell & Gene Therapy of Cancer Annual Meeting; Amsterdam, The Netherlands September 27<sup>th</sup> 2014.
125. "Leadership in Discovery" Women in Science and Entrepreneurship Conference; St. Louis, MO, November 14<sup>th</sup> 2014.
126. "Unleashing the Power of Comparative Models in Biomedical Research" University College of Dublin Zoetis Sponsored Invited Lecture on One Health; Dublin, Ireland, March 23<sup>rd</sup> through 25<sup>th</sup> 2015
127. "Unleashing the power of A One health approach to medicine and science." Keynote Address, Auburn University College of Veterinary Medicine 108<sup>th</sup> Annual Conference; Auburn, AL, March 27th 2015.
128. "One Health Connections – "Now We're Talking" One Health Summit Keynote Address; Kansas City, MO, March 31<sup>st</sup> 2015.
129. "One Health Challenges for the 21s Century" Keynote Presentation for One Health: Integrating the Veterinarian Scientist into the Biomedical Research Enterprise, Office of Research Infrastructure Programs Workshop; NIH; Bethesda, MD, April 7<sup>th</sup> 2015
130. "Viruses Treating Cancer" Missouri Cures Cancer Research Symposium; Danforth Center, St. Louis, MO, May 1<sup>st</sup> 2015.
131. "One Health: Clear Vision & Blurred Lines." University of Tennessee Research Symposium; Knoxville, TN, May 18<sup>th</sup> 2015.
132. "The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research." Participated on the panel, National Cancer Policy Forum Workshop; Washington, DC, June 8<sup>th</sup> & 9<sup>th</sup> 2015.
133. "The Big Five: Malignant Lymphoma, Mast cell tumours, Melanoma, Mammary tumours and Oral Squamous Cell Carcinoma " speaker and panel member, ONCOlogisch Treffen; Soesterberg, The Netherlands, Feb 6 and 7, 2016.
134. "Just Because We Can, Doesn't Mean We Should" American College of Veterinary Internal Medicine Forum, Oncology Specialty Session, Denver, Co, June 8, 2016.
135. "Bladder Cancer: A Medical Oncologist's Perspective" Veterinary Eastern Cooperative Oncology Group Meeting, NYC, New York, April 10, 2016.
136. "Howling at the Cancer Moonshot", KCALSI Collaborate2Cure, Immunotherapy- Cancer and Beyond Seminar Series, Kansas City, MO and on Zoom, November 3, 2016.
137. "The One Health Initiative Impact on Veterinary Bills, Senate Bills, and Dollar Bills" 125<sup>th</sup> Missouri Veterinary Medical Association Annual Convention, Columbia, MO, January 19-22, 2017.